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Preamble
Guidelines and Expert Consensus Documents summarize and
evaluate all currently available evidence on a particular
issue with the aim to assist physicians in selecting the best
management strategies for a typical patient, suffering
from a given condition, taking into account the impact on
outcome, as well as the risk–beneﬁt ratio of particular diag-
nostic or therapeutic means. Guidelines are not substitutes
for textbooks. The legal implications of medical guidelines
have been discussed previously.
A great number of Guidelines and Expert Consensus Docu-
ments have been issued in recent years by the European
Society of Cardiology (ESC) as well as by other societies
and organizations. Because of the impact on clinical prac-
tice, quality criteria for development of guidelines have
been established in order to make all decisions transparent
to the user. The recommendations for formulating and
issuing ESC Guidelines and Expert Consensus Documents
can be found on the ESC web site (http://www.escardio.
org/knowledge/guidelines/rules).
In brief, experts in the ﬁeld are selected and undertake a
comprehensive review of the published evidence for man-
agement and/or prevention of a given condition. A critical
evaluation of diagnostic and therapeutic procedures is per-
formed, including assessment of the risk–beneﬁt ratio.
Estimates of expected health outcomes for larger societies
are included, where data exist. The level of evidence and
the strength of recommendation of particular treatment
options are weighed and graded according to predeﬁned
scales, as outlined in the tables below.
The experts of the writing panels have provided disclosure
statements of all relationships they may have which might
be perceived as real or potential sources of conﬂicts of
interest. These disclosure forms are kept on ﬁle at the Euro-
pean Heart House, headquarters of the ESC. Any changes in
conﬂict of interest that arise during the writing period must
be notiﬁed to the ESC. The Task Force report was entirely
supported ﬁnancially by the ESC and was developed
without any involvement of industry.
The ESC Committee for Practice Guidelines (CPG) super-
vises and coordinates the preparation of new Guidelines
and Expert Consensus Documents produced by Task Forces,
expert groups, or consensus panels. The Committee is also
responsible for the endorsement process of these Guidelines
and Expert Consensus Documents or statements. Once the
document has been ﬁnalized and approved by all the
experts involved in the Task Force, it is submitted to
outside specialists for review. The document is revised,
and ﬁnally approved by the CPG and subsequently published.
After publication, dissemination of the message is of para-
mount importance. Pocket-sized versions and personal
digital assistant (PDA)-downloadable versions are useful
at the point of care. Some surveys have shown that
the intended end-users are sometimes not aware of the
existence of guidelines, or simply do not translate them
into practice, so this is why implementation programmes
for new guidelines form an important component of the dis-
semination of knowledge. Meetings are organized by the
ESC, and directed towards its member National Societies
and key opinion leaders in Europe. Implementation meetings
can also be undertaken at national levels, once the guide-
lines have been endorsed by the ESC member societies,
and translated into the national language. Implementation
programmes are needed because it has been shown that
the outcome of disease may be favourably inﬂuenced by
the thorough application of clinical recommendations.
Thus, the task of writing Guidelines or Expert Consensus
documents covers not only the integration of the most
recent research, but also the creation of educational tools
and implementation programmes for the recommendations.
The loop between clinical research, writing of guidelines,
and implementing them in clinical practice can then only
be completed if surveys and registries are performed to
verify that real-life daily practice is in keeping with what
is recommended in the guidelines. Such surveys and regis-
tries also make it possible to evaluate the impact of
implementation of the guidelines on patient outcomes.
Guidelines and recommendations should help the physicians
to make decisions in their daily practice; however, the ulti-
mate judgement regarding the care of an individual patient
must be made by the physician in charge of his/her care.
Classes of recommendations
Class I Evidence and/or general agreement that a
given treatment or procedure is beneﬁcial,
useful, and effective
Class II Conﬂicting evidence and/or a divergence of
opinion about the usefulness/efﬁcacy of the
given treatment or procedure
Class IIa Weight of evidence/opinion is in favour of
usefulness/efﬁcacy
Class IIb Usefulness/efﬁcacy is less well established by
evidence/opinion
Class III Evidence or general agreement that the given
treatment or procedure is not useful/
effective, and in some cases may be harmful
Levels of evidence
Level of evidence A Data derived from multiple randomized
clinical trials or meta-analyses
Level of evidence B Data derived from a single randomized
clinical trial or large non-randomized
studies
Level of evidence C Consensus of opinion of the experts and/
or small studies, retrospective studies,
registries
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Introduction
The rationale for an active approach to the prevention of
atherosclerotic cardiovascular disease (CVD) is based on
ﬁve key points:
By the early 1990s there was a plethora of similar yet con-
fusingly different national and international guidelines for
the prevention of CVD. In order to try to deﬁne the areas
of agreement, the ESC, the European Atherosclerosis
Society and the European Society of Hypertension agreed
to collaborate, resulting in a set of recommendations for
the prevention of coronary heart disease (CHD) that was
published in 1994.1 These guidelines were revised in 1998
and 2003 by the second and third Joint Task Forces.2,3 A
strength of the guidelines is that, from the outset, it was
stressed that CVD is usually the product of multiple interact-
ing risk factors. This resulted in the production of risk charts
that attempt to simplify the estimation of total CVD risk,
and a realization that risk management requires attention
to all modiﬁable risk factors.
It was appreciated that the original partners needed
assistance from other bodies and experts, in particular in
the ﬁelds of behavioural medicine and diabetes. In addition,
it is acknowledged that much practical preventive advice is
delivered by family doctors, nurses, and through voluntary
bodies such as Heart Foundations. These considerations
are reﬂected in the expanded partnership represented in
the present guidelines, and in the list of experts whose
input has been sought.
The Third Joint Task Force Guidelines saw a change from
CHD to CVD prevention, to reﬂect the fact that athero-
sclerosis may affect any part of the vascular tree. A new
risk chart called SCORE (Systematic COronary Risk Evalu-
ation) was developed which was based on 12 European
cohort studies and allowed the estimation of 10-year risk
of cardiovascular death. Separate charts were produced
for high and low risk regions of Europe. More explicit clinical
priorities were developed. Less emphasis was placed on the
terms ‘primary’ and ‘secondary’ prevention since risk is a
continuum—asymptomatic persons may have investigational
evidence of atherosclerotic disease. A rigorous external
review process was undertaken.
The Fourth Joint Task Force has taken note of feedback in
several areas:
(1) More detailed guidance was sought from the World
Organization of National Colleges, Academies and aca-
demic associations of general practitioners/family phys-
icians (WONCA, or the ‘World Organization of Family
Doctors’ for short) and from the ESC Working Group on
Cardiovascular Nursing, since these bodies represent
the professionals that are heavily engaged in the practical
delivery of preventive advice in many European countries.
(2) The current ESC approach to grading evidence was
examined in detail. Concern was expressed that the
present system, while logical, tends to give priority to
drug treatments since these are more amenable to
double-blind randomized controlled trials than lifestyle
measures, even if observational studies indicate power-
ful beneﬁts from, for example, smoking cessation. For
this reason, the gradings have not been included in the
present documents, and further debate on this topic is
strongly recommended.
(3) All risk estimation systems, including SCORE, will overesti-
mate risk in countries that have experienced a decline in
CVD mortality, and underestimate risk if mortality has
increased. The development of national guidance has
always been recommended by the Task Force and, as part
of this process, recalibration of the SCORE charts to allow
for time trends in both mortality and risk factor distri-
butions in individual countries is recommended. In the
Third Joint Guidelines, the need to address the problem
of a high relative but low absolute risk in younger persons
was dealt with by extrapolating a young person’s risk to
age 60 to ﬂag persons who will become at high absolute
risk. If interpreted too literally, this approach might
result in excessive use of drug treatments in young
people. In the present guidelines, this approach has been
replacedwith a simple relative risk chart to be used in con-
junction with the SCORE absolute risk chart.
(4) A re-examination of the SCORE data sets indicated that
the impact of self-reported diabetes on risk may have
been underestimated. The issue of predicting total
events as well as just CVD mortality also receives more
attention, as do gender issues, central obesity, high-
density lipoprotein (HDL) cholesterol, heart rate, renal
impairment, and manifestations of CVD other than CHD.
These Guidelines attempt to ﬁnd areas of broad agreement
among different professional bodies and scientiﬁc disciplines.
With the help of WONCA, a particular effort has beenmade to
ESC Guidelines2378
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harmonize the advice that may be given to primary care and
second-line care health professionals. The production of
more detailed guidelines by the partner societies is encour-
aged; as examples, reference is made to the ESH/ESC guide-
lines on the management of arterial hypertension4 and to
the guidelines on diabetes, pre-diabetes and CVD by the
ESC/EASD.5 Implicit in this partnership process is that these
will be compatible with the generic Joint Guidelines.
The development of national guidance on CVD prevention
is also speciﬁcally encouraged. The Joint Guidelines should
be regarded as a framework from which national guidelines
can be developed to suit local political, economic, social,
and medical circumstances. The production of guidelines is
only one step in the process of prevention, and the develop-
ment of national multidisciplinary implementation partner-
ships is recommended; the section on implementation
addresses some of the issues involved.
It should be appreciated that the Fourth Joint Task Force
Guidelines are for the use of physicians and other health pro-
fessionals engaged in clinical practice. Therefore, they give
the highest priority to those individuals at highest CVD risk
because such persons gain most by active risk factor manage-
ment. However, they should be complemented by national
and European public health strategies aimed at whole popu-
lations in a co-ordinated and comprehensive effort to
reduce the enormous burden of CVD that afﬂicts European
populations. In this way, we hope that the guidelines will
promote higher quality of care to help reduce this burden
andCVD in Europe. These issues informamajor new initiative,
the publication of the European Health Charter, available
through www.heartcharter.eu. The Charter was produced by
the ESC, European Union (EU), and the European Heart
Network, in partnership with the World Health Organization
(WHO). The relationship between the Charter and the
present Guidelines may be summarized:
The scope of the problem: past and future
Scientiﬁc background
CVDs were the direct cause of .4 million deaths in Europe
around the year 2000 (1.9 million in the EU), accounting for
43% of all deaths of all ages in men and for 55% in women
(Table 1 from www.ehnheart.org6).7 CVDs were also the
major cause of hospital discharges, with an average rate of
2557 per 100 000 population around the year 2002. Out
of these, 695 per 100 000 were caused by CHD and 375 per
100 000 by stroke, but more than half were due to other
forms of chronic heart disease. The estimated total cost of
CVDs in the EU countries was E168 757 million in 2003.8
CVD mortality rates vary with age, gender, socio-economic
status, ethnicity, and geographical region. Mortality rates
increase with age, and are higher in men, in people of low
socio-economic status, in Central and Eastern Europe, and in
immigrants of South Asian origins. There are marked socio-
economic gradients in CVD morbidity and mortality within
European countries, which are partially explained by socio-
economic differences in conventional risk factors, such as
smoking, blood pressure (BP), blood cholesterol, and glucose.
Total CVD mortality has been falling consistently, both in
middle life and at older ages, since 1970 in Western
Europe.9 In Central and Eastern Europe, they started to
decline only in recent years, and they remain very high in
such countries. There is still nearly a 10-fold gradient in
male CHD mortality between Eastern Europe and France at
ages 35–74, and up to a 6-fold difference in stroke mortality.
Declines in CHD mortality are related to population-wide
behavioural changes in nutrition and smoking in both
Western and Eastern Europe. The incidences of CHD10 and
stroke have also been declining in Western Europe, but
increasing in other countries, principally in Eastern Europe
and Spain.
Practical aspects: coronary artery disease
Changes in CHD mortality at the end of the 20th century
were mostly explained by changes in incidence rather than
changes in short-term case fatality of acute myocardial
infarction (AMI).11 Major emphasis is needed in the control
of risk factors and of the determinants of incident CHD.
The reduction in blood pressure noted at population level is
only partly attributable to an increase in the proportion of
hypertensive subjects receiving treatment, suggesting that
despite the importance of medication to individuals, other
determinants of BP lowering are more powerful in whole
populations. Risk factor control in high risk patients and in
patients with established CHD remains poor, especially
regarding obesity, smoking, and BP, and mostly so in diabetic
patients, in spite of issued guidelines indicating the need for
reinforcing dissemination and implementation of cost-
effective prevention actions in an organized way.12
As survival after acute events improves, prevalent CHD
increases, especially in older women. It is known that dia-
betes is a more powerful risk factor for women, and, thus,
control of risk factors among diabetic patients becomes a
Table 1 All deaths from circulatory disease in Europe. All ages.
Year 2000 or circa
All causes Men 4 519 403
Women 4 336 346
All circulatory Men 1 963 644
Women 2 307 945
CHD Men 967 258
Women 983 229
Stroke Men 504 307
Women 775 571
Other Men 492 079
Women 637 405
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special priority. As the prevalence of overweight and obesity
increases worldwide, an increase in the prevalence of type 2
diabetes and hence all its complications may be anticipated.
Consequently, control of the growing epidemic of obesity
should be a priority.
The clinical manifestations of CVD may be very different.
Hospital statistics reveal only the tip of the iceberg, since
sudden cardiac death occurring outside the hospital still
represents a large proportion of all cardiovascular deaths.
Heart failure
Pump failure of the heart is a common cause of death in the
elderly, although this not always reﬂected in mortality stat-
istics because of the limitations of coding rules. Hospital
admission rates for heart failure have been increasing in
the USA and in Europe. Hypertension, obesity, and diabetes
are major risk factors. Although a small proportion of clini-
cal cases are due to valve disease (often linked with CHD),
or to cardiomyopathy, epidemiological studies suggest
that, in well developed countries, the majority of cases
are due to ischaemia.13
Aortic aneurysm and dissection
Aortic aneurysm is also atherosclerotic in nature, and
increasing mortality trends have been shown in some Euro-
pean countries.14 It is a potentially preventable cause of
death, particularly when conﬁned to the abdominal aorta.
The prevalence is 5% in men aged 60 years or more, and
1–2% in women. Screening for this condition has been
suggested since elective surgical repair carries a 5–8%
30-day mortality in comparison with 50% mortality for rup-
tured aneurysm; a trial of screening conducted in the UK
has shown encouraging results.15
Peripheral arterial disease
It is known that coronary and peripheral vessels are affected
by the same disease process, requiring the same treatment
modalities. Peripheral arterial disease (PAD) occurs almost
as frequently in women as in men.16 The correlation of
PAD with CHD, myocardial infarction (MI), and stroke reﬂects
the widespread nature of atherosclerosis. However, some
minor differences have emerged from epidemiological
studies regarding the risk factors for these diseases.
Smoking appears to be more important in the aetiology of
PAD than in CHD.17 A positive family history, hypertension,
diabetes, dyslipidaemia including increased total and low-
density lipoprotein (LDL) cholesterol and decreased HDL
cholesterol, increased ﬁbrinogen and C-reactive protein
(CRP), advanced age, and physical inactivity seem to be
common risk factors.
As inCHD, effective risk factormanagement is essential. Risk
reduction can be achieved through lifestyle modiﬁcation, par-
ticularly physical activity and exercise, smoking cessation, and
therapies such as use of statins, antiplatelet therapies, antith-
rombotic strategies, angiotensin-converting enzyme (ACE)
inhibitors, and b-blockers.16,18,19 The beneﬁcial effects of
statins in these patients have been shown in large trials.20
Statins not only lower the risk of PAD and vascular events, but
they also improve the symptoms associated with PAD. There
is also evidence that statins reduce surgical mortality and
improve graft patency and limb salvage in PAD patients.21
Stroke
The incidence of stroke increases exponentially with age,
affecting about 25 per 100 000 in the age group 35–44
years and 1500 per 100 000 in age group 75–84 years
annually. Stroke is the third leading cause of death in
many countries. Intracerebral haemorrhage and subarach-
noid haemorrhage contribute 10 and 5% of strokes, respect-
ively. Ischaemic stroke may be due to large vessel disease,
small vessel disease, emboli from the heart or from the
aortic arch, or other rarer identiﬁed causes, while a large
proportion still remains undetermined.22
The most important risk factor is hypertension, followed
by smoking and diabetes. Others are sedentary lifestyle,
overuse of alcohol, and illicit drugs, elevated cholesterol,
use of oral contraceptives or postmenopausal hormones,
overweight, low socio-economic status (SES), and athero-
sclerotic stenosis of extracranial vessels.
Practical aspects: prevention and management
of stroke
Antihypertensive treatment reduces risk of both ischaemic
and haemorrhagic stroke, and stroke prevention is the
most important effect of antihypertensive treatment.
Smoking should be discouraged and physical activity
encouraged. Alcohol intake in low amounts may not be
harmful. With regard to statin therapy, stroke survivors
should be treated in the same way as those with other
manifestations of CVD. Carotid endarterectomy in sympto-
matic patients with stenosis of the internal carotid artery
reducing the lumen .70% reduces the risk of recurrent
stroke.
Prophylactic antithrombotic treatment: Within the thera-
peutic range of international normalized ratio (INR) 2–3,
anticoagulation reduces stroke risk in patients with atrial
ﬁbrillation. Antiplatelet therapy is indicated in patients
with non-cardioembolic ischaemic stroke. Aspirin is the
most widely used drug in doses of 75–150 mg a day. The com-
bination of aspirin and dipyridamole gives an additional risk
reduction. Clopidogrel has an effect similar to aspirin in
patients with ischaemic cerebrovascular disease. Combi-
nation of clopidogrel and aspirin is not recommended for
stroke survivors. For a more comprehensive review,
readers are referred to the European Stroke Initiative.23
Prevention strategies and policy issues
Scientiﬁc background
Three strategies for the prevention of CVD can be distin-
guished: population, high-risk and secondary prevention.
The three strategies are necessary and complement
each other. The population strategy in particular is critical
to reducing the overall incidence of CVD since it aims to
reduce risk factors at population level through lifestyle
and environmental changes that affect the whole population
without requiring the medical examination of individuals.
This type of strategy is mostly achieved by establishing ad
hoc policies and community interventions.
The strategies aimed to diminish the total cardiovascular
risk of individuals are the high risk primary prevention and
the secondary prevention strategies. The former deals
with healthy persons belonging to the upper part of the
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risk distribution, and the second with patients with estab-
lished cardiovascular organ damage or disease. To prevent
one single cardiovascular event, it will be necessary to inter-
vene in many subjects with no apparent beneﬁt to them
(prevention paradox). Furthermore, the number of subjects
in whom an intervention is needed to prevent one case will
vary in different populations or population subgroups (e.g.
in women) depending on their underlying prevalences and
distribution of risk factors, and the incidence rate of
disease.
Practical aspects: policy issues
The Fourth Task Force aligns and fully endorses the initiat-
ives of major international organizations in taking steps to
implement measures at the population level, such as those
for tobacco control established by the WHO Framework Con-
vention for Tobacco Control,24 the EU initiative on obesity,25
the WHO Global Strategy on diet, physical activity, and
health,26 and the Osaka Declaration on Heart Health which
can be summarized as:
\
Likewise, the EU Council on Employment, Social Policy,
Health, and Consumer Affairs in June 2004 and an EU
Heart Health Conference that resulted in the Luxembourg
Declaration of 29 June 2005 deﬁned the characteristics
that are necessary to achieve cardiovascular health:
† Avoidance of tobacco
† Adequate physical activity (at least 30 min per day)
† Healthy food choices
† Avoiding overweight
† BP below 140/90 mmHg
† Total cholesterol below 5 mmol/L (200 mg/dL).
The Fourth Task Force encourages health professionals of
all countries to participate actively in the design and
implementation of such national and international policies
and community interventions.
Prevention in clinical practice
There is no evidence that mass screening for detection of
early stages of CHD or stroke is a cost-effective way to
prevent disease. For opportunistic detection of biological
risk factors or of lifestyles to detect persons at high risk,
the following are necessary:
† accurate and adequate systems of measurement are
routinely available
† real time for advice or treatment as appropriate
† continuity of care
† patient access to treatments, regardless of SES.
Programmes for secondary prevention of CHD have proven
to be effective in improving processes of care, readmissions
to hospital, functional status, and overall mortality,
especially if they incorporate exercise programmes.
However, their effect sizes are quite modest and their cost-
effectiveness on a large scale remains uncertain.27,28
How to evaluate scientiﬁc evidence
Scientiﬁc background
Evidence-based medicine (EBM) has been deﬁned as the
integration of individual clinical expertise with the best
available clinical evidence from systematic research. It
involves asking answerable questions, searching for the
best evidence, critically appraising the evidence, applying
the evidence to individual patient care, and evaluating the
process.29 Despite over a decade of educational effort, it
is rare for clinicians to practise EBM as intended, with
many considering that the major issue is ﬁnding the
evidence.30
This report aims to provide guidelines under the auspices
of the Fourth Joint Task Force of the ESC and other European
Societies on Cardiovascular Disease Prevention. The Task
Force wishes these guidelines to be as evidence based as
possible. Good guidelines are a major mechanism for
improving the delivery of health care and improving
patient outcomes.31 It has been shown that guidelines
based on credible evidence are more likely to be adopted.32
What is ‘evidence’?
The evaluation of interventions and diagnostic methods can
make use of a wide range of sources of evidence: experi-
ence, retrospective case review, case reports, case series,
historic and geographic comparisons, drug (and post-
marketing) surveillance studies, pharmacoepidemiological
databases, cross-sectional studies, case–control studies,
cohort studies, randomized controlled trials, and systematic
reviews of trials and of observational studies. Traditionally,
hierarchies of evidence have been promoted as a means of
prioritizing recommendations. These generally put systema-
tic reviews at the top of the hierarchy and case reports at
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the bottom. However, this approach may be misleading as
the quality of evidence ultimately depends on the question
to be answered.
It is clear that different questions require different scien-
tiﬁc methods, and that reliance on one source of evidence to
the exclusion of others is likely to be misleading. This is par-
ticularly true in CVD prevention. Lifestyle measures such as
smoking cessation, exercise, and healthy eating are less
amenable to double blind randomized controlled trials
than are drug treatments, and to promote slavish adherence
to the primacy of the randomized controlled trial may result
in guidelines that promote excessive usage of drugs. Sys-
tematic reviews and randomized controlled trials are not
the most appropriate method for identifying rare hazards
of treatment. Case reports may provide the ﬁrst hint that
a treatment is hazardous, but they require conﬁrmation in
large prospective surveillance surveys.
Grading of evidence
In using evidence to produce guidance or recommendations
for clinical or public health practice, it is important to dis-
tinguish between the quality of the evidence (is it robust,
little likelihood of bias, generalizable, etc.) and the strength
of a recommendation underpinned by the evidence. Not all
high quality evidence merits a strong recommendation.
Guideline developing bodies have generally used the
‘hierarchy of evidence approach’. Application of the hierar-
chy of evidence method requires explicit judgements to be
made about the quality of the evidence (e.g. completeness,
potential for bias, adequacy of outcomes assessed, etc.)
Critically, both the beneﬁts and the hazards of interventions
need to be taken into account in producing clinical
guidance. While such an approach provides transparency,
there are also disadvantages, as outlined above. There
have also been difﬁculties in the implementation of these
graded recommendations. For example, in implementing
a guideline, some recommendations that are crucial to
the overall improvement of care may be underpinned by
little or no strong evidence. If a decision to implement
only high grade recommendations was undertaken on the
grounds of resource constraints, then important elements
of the guideline may be overlooked. Consequently, there is
interest in developing a system that retains the desirable
ability to maintain transparency but avoids perversity in
implementation.
The WHO have established a working group to develop
such a system, called GRADE. Evidence is graded based on
the outcomes relevant to the question being answered.
This is appraised in four domains: study design, study
quality, consistency, and directness (generalizability).
Based on the scoring of these attributes, the quality of evi-
dence for the speciﬁc outcome is deﬁned as high, moderate,
low, or very low grade.33 This system cannot tackle the
implementation problems discussed above but provides a
clear judgement of whether the beneﬁts of an intervention
outweigh the adverse effects. This provides a transparent
method of prioritizing interventions for implementation.
As experience in using this system grows, it will probably
become a more widely used tool for the generation of clini-
cal guidance.
The problems of evidence and guidance
We have attempted to ensure that the most appropriate evi-
dence is used to underpin recommendations. For population
prevention programmes, observational epidemiological ﬁnd-
ings are an important ﬁrst step in considering causality.
Behaviours such as smoking cessation and exercise are less
amenable to randomized controlled trials than drug treat-
ments. Clearly, systematic reviews of observational studies
are preferable to citation of single observational studies.
However, it is important to be aware that the increased pre-
cision provided by pooling data may be spurious if the
control for confounding and other biases is weak in the
index studies.34
A growing concern in epidemiology is that with some
associations causation has been wrongly attributed. This
appears to be the case for antioxidant vitamins, where
observational studies suggested a reasonable protective
effect, but randomized controlled trials have shown that
the interventions may even be harmful.35,36 A further
concern for us is the nature of available evidence. Much of
the evidence concerns drug treatments rather than lifestyle
interventions or health system improvements.
In examining the effects of interventions, we have given
prominence to Cochrane systematic reviews where they
exist as these are conducted to a rigorous standard and
are updated periodically. We have used other systematic
reviews where these exist and have only cited individual
trials where they make particular points of interest, or are
sufﬁciently large to provide a clear answer to a clinical ques-
tion. Where we feel the evidence is scant, we have stated
this.
When examining effect sizes, we have not used numbers
needed to treat as these have quite marked problems,37 par-
ticularly in preventive cardiology where baseline rates of
CVD vary markedly throughout Europe. Consequently a
number needed to treat would be needed for countries
with low, medium, and high risk. Moreover, numbers
needed to treat for different age groups and for men and
women would be required. Relative risk reductions on treat-
ment are applicable to all European populations, age
groups, and men and women as, in general, most treatments
have the same relative beneﬁts at different levels of risk.
Practical aspects
In this report, we have attempted to follow an evidence-
based approach. We have deﬁned the following questions:
† What is the evidence that speciﬁc risk factors cause CVD?
† What is the evidence that these risk factors vary in
importance among those with and without established
CVD?
† What is the evidence that interventions for populations
lead to reductions in risk factors and CVD outcomes?
† What is the evidence that interventions for individuals
lead to reductions in risk factors and CVD outcomes?
We have systematically and critically reviewed the rel-
evant literature to answer each question posed. Certain dif-
ﬁculties are apparent with regard to the current ESC
hierarchical grading system. The present system is likely to
favour drug treatments over major lifestyle measures
because the latter are less amenable to double-blind
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randomized controlled trials. For this reason, after pro-
longed debate, the Task Force has not included the table
of the grades that it prepared. However, it is anticipated
that this issue will require further debate.
Efforts have been made to implement the guidelines
through the various participating societies. Previous guide-
lines have been evaluated by means of EUROASPIRE I and
II.38,39
Priorities, total risk estimation, and objectives
Introduction
At the outset, it is stressed that these guidelines are just
that, and not didactic rules. They should be interpreted in
the light of the clinician’s own knowledge and judgement,
the patient’s view, and in the light of local conditions and
practicalities and as new knowledge becomes available.
Indeed the development of national guidelines is strongly
encouraged, with objectives, priorities, and implementation
strategies that are adapted to suit local conditions, both
medical and economic.
The priorities suggested are to assist the physician in
dealing with individual people and patients. As such, they
acknowledge that individuals at the highest levels of risk
gain most from risk factor management. As noted else-
where, although such individuals gain most, most deaths in
a community come from those at lower levels of risk,
simply because they are more numerous compared with
high risk individuals who, paradoxically, develop fewer
events in absolute terms—the Rose Paradox.40 Thus a strat-
egy for individuals at high risk must be complemented by
public health measures to reduce, as far as is practicable,
population levels of cardiovascular risk factors and to encou-
rage a healthy lifestyle.
The encouragement of total risk estimation as a crucial
tool to guide patient management has been a cornerstone
of the Guidelines since the ﬁrst (1994) edition.1 This is
because clinicians treat whole people (and not individual
risk factors), whose cardiovascular risk usually reﬂects the
combined effects of several risk factors that may interact,
sometimes multiplicatively.
Although clinicians often ask for thresholds to trigger
intervention, this is problematic since risk is a continuum
and there is no exact point where, for example, a drug is
automatically indicated. This issue is dealt with in more
detail, as is the issue of how to advise younger persons at
low absolute but high relative risk, and the fact that all
elderly people will eventually be at high risk of death and
may be overexposed to drug treatments.
The overall objectives of cardiovascular prevention are to
reduce mortality and morbidity in those at high absolute risk
and to assist those at low absolute risk to maintain this
state, through a healthy lifestyle. Here, the risk charts are
helpful—if BP is hard to control fully, for example, total
risk can still be reduced by stopping smoking or perhaps
reducing cholesterol levels further. Although thresholds for
total cardiovascular risk included in this guideline are arbi-
trary, targets for individual risk factors are even more pro-
blematic in that they will always be open to debate, are
not always achievable, and, notably, because they seem to
promote a uni-risk factor approach to prevention. Yet clini-
cians ask for guidance, so an attempt to deﬁne desirable
levels of individual risk factors has been made in the
context of more speciﬁc objectives.
Priorities
Individuals at highest risk gain most from preventive efforts,
and this guides the following priorities:
What are the objectives of cardiovascular disease
prevention?
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In general, a middle aged person with a 10-year risk of
CVD death of 5% or more is regarded as at high risk. Examin-
ation of the FINRISK MONICA data (which contribute substan-
tially to the SCORE high risk population charts) suggests that
the equivalent total (fatal þ non-fatal) CVD risk is about
10%—more in younger men and less in women and the
eldery. The likelihood of requiring medication in addition
increases with increasing risk.
Total risk estimation
Total cardiovascular risk in the context of these guidelines
means the likelihood of a person developing an atherosclero-
tic cardiovascular event over a deﬁned period of time.
The importance of total risk estimation before manage-
ment decisions are made is illustrated in Table 2 and
Figure 1. The ﬁgure illustrates that the effect of lipid
levels on risk is modest in women who are at otherwise
low risk, and that the risk advantage of being female is
lost by the combination of smoking and mild hypertension.
Table 2 shows that a person with a total cholesterol of
8 mmol/L can be at 10 times lower risk than someone with
a total cholesterol of 5 mmol/L if the latter is a male hyper-
tensive smoker. Randomized controlled drug trials of single
risk factors do not give sufﬁcient data to address these
issues fully. While audits such as EuroAspire38,39 suggest
inadequate risk factor management in very high risk sub-
jects, it is also likely that, in the context of low risk subjects
who have not had a vascular event, there is the potential for
substantial overuse of drugs by inappropriate extrapolation
of the results of trials conducted mostly on high risk men
to low risk individuals. In general, women and old and
young subjects have been under-represented in the classic
drug trials that have informed guidelines to date.
For these considerations to impact on clinical practice, it
is essential for the clinician to be able to assess risk rapidly
and with sufﬁcient accuracy to allow logical management
decisions.
How do I assess risk?
The need to assess total risk easily and quickly led to the
development of the risk chart used in the 1994 and 1998
Guidelines.1,2,41 There were several problems with this
chart. First, it was derived from American data from the
Framingham study and the applicability of the chart to all
European populations was uncertain. Secondly, the data
set used was fairly small. Thirdly, the deﬁnitions of non-fatal
CHD events differed from those used in many other studies,
making it difﬁcult to validate the chart. Finally, estimation
of the risk of other manifestations of atherosclerosis such
as stroke or aneurysm of the abdominal aorta was not
possible.
The 2003 Guidelines3 used a new system for risk esti-
mation called SCORE,42 based on data from 12 European
cohort studies, and includes 205 178 subjects examined at
baseline between 1970 and 1988 with 2.7 million years of
follow-up and 7934 cardiovascular deaths.
Risk charts such as SCORE are intended to facilitate risk
estimation in ostensibly healthy persons. Patients who
have had a clinical event such as an acute coronary syn-
drome or stroke, who have type 2 diabetes or type 1 dia-
betes with microalbuminuria, or who have a markedly
increased level of a single risk factor have already declared
themselves to be at markedly increased risk and automati-
cally qualify for intensive risk factor evaluation and
management.
Figure 1 The relationship of total cholesterol (TC):HDL cholesterol ratio to
10-year fatal CVD events in men and women aged 60 years with and without
risk factors, based on a risk function derived from the SCORE project. SBP ¼
systolic blood pressure.
Table 2 Impact of combinations of risk factors on risk
Sex Age
(years)
Cholesterol
(mmol/L)
BP
(mmHg)
Smoker Risk
(%)
F 60 8 120 No 2
F 60 7 140 Yes 5
M 60 6 160 No 8
M 60 5 180 Yes 21
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SCORE differs from earlier risk estimation systems in
several important ways, and has been modiﬁed somewhat
for the present guidelines:
† The SCORE system estimates the 10-year risk of a ﬁrst
fatal atherosclerotic event, whether heart attack,
stroke, aneurysm of the aorta, or other. All ICD (Inter-
national Classiﬁcation of Diseases) codes that could
reasonably be assumed to be atherosclerotic are
included. Most other systems estimate CHD risk only.
† The choice of CVD mortality rather than total (fatal þ non-
fatal) events was deliberate although not universally
popular. Non-fatal event rates are critically dependent
upon deﬁnitions and the methods used in their ascertain-
ment. Striking changes in both diagnostic tests and thera-
pies have occurred since the SCORE cohorts were
assembled. Critically, the use of mortality allows
re-calibration to take into account time trends in CVDmor-
tality. Any risk estimation system will overpredict in
countries in which mortality has fallen and underpredict
in those in which it has risen. Recalibration to allow for
secular changes can be undertaken if good quality,
up-to-date mortality and risk factor prevalence data are
available. Data quality does not permit this for non-fatal
events. For these reasons, the CVD mortality charts were
produced and have, indeed, been re-calibrated for a
number of European countries. Country-speciﬁc versions
of HeartScore are available for Belgium, Germany,
Greece, The Netherlands, Poland, Spain, and Sweden.
Nevertheless it is essential to address the issue of total risk.
In the 2003 Guidelines,3 a 10-year risk of CVD death of 5%
or more was arbitrarily considered high risk. Yet this implies
a 95% chance of not dying from CVD within 10 years, less
than impressive when counselling patients. The new nomen-
clature in this 2007 Guideline is that everyone with a 10-year
risk of CVD death of 5% or more has an increased risk. Natu-
rally the risk of total fatal and non-fatal events is higher, and
clinicians naturally wish for this to be quantiﬁed. The
biggest contributor to the high risk SCORE charts is
FINRISK, which has data on non-fatal events deﬁned accord-
ing to the MONICA project.43 Calculating total event rates
from FINRISK suggests that, at the level (5%) at which risk
management advice is likely to be intensiﬁed, total event
risk is about 10%, more (15%) in younger men and somewhat
less in women. The ‘multiplier’ to convert CVD mortality to
total events is also smaller in older people, presumably
because a ﬁrst event is more likely to be fatal.
As noted in the Introduction, clinicians often ask for
thresholds to trigger certain interventions, but this is pro-
blematic since risk is a continuum and there is no threshold
at which, for example, a drug is automatically indicated. A
particular problem relates to young people with high
levels of risk factors—a low absolute risk may conceal a
very high relative risk. In the 2003 Guidelines,3 it was
suggested to extrapolate risk to age 60 to stress that a
high absolute risk would occur if preventive action were
not taken. It was not intended that such a young person
should be necessarily treated as if they were 60, but a
literal interpretation of this suggestion could lead to
excessive drug treatment in younger persons. This part of
the text has been rephrased, and a relative risk chart
added to the absolute risk charts to illustrate that, particu-
larly in younger persons, lifestyle changes can reduce risk
substantially, as well as reducing the increase in risk that
will occur with ageing.
† Another problem relates to old people. In some age cat-
egories, the vast majority, especially of men, will have
estimated CVD death risks exceeding the 5–10% threshold,
based on age (and gender) only, even when other CVD risk
factor levels are relatively low. This could lead to exces-
sive usage of drugs in the elderly. Preventive treatments
in the elderly should be evidence based unless clearly
indicated.
† As before, charts are presented for both total cholesterol
and the cholesterol:HDL cholesterol ratio. They look
remarkably similar. However, subsequent work on the
SCORE database, as yet unpublished, has shown that
HDL cholesterol can contribute substantially to risk pre-
diction if entered as an independent variable.
† Dealing with the impact of additional risk factors such as
HDL cholesterol, body weight, family history, and newer
risk markers is difﬁcult within the constraint of a paper
chart. The electronic, interactive version of SCORE,
HeartScore (available through escardio.org), is not so con-
strained. It presently replicates SCORE in electronic
format, but will be used to accommodate the results of
new SCORE analyses, such as those relating to HDL choles-
terol, as these are checked and validated. It should be
stressed, however, that although many risk factors other
than the few included in the available risk functions
have been identiﬁed (such as CRP and homocysteine
levels), their contribution to absolute CVD risk esti-
mations of individual patients (in addition to the older
risk factors) is generally modest.
† The impact of self-reported diabetes has been
re-examined. While there is heterogeneity between
cohorts, overall the impact of diabetes on risk appears
greater than in risk estimation systems based on the Fra-
mingham cohort, with relative risks of approximately ﬁve
in women and three in men.
Some of the advantages of using the risk charts may be
summarized:
Advantages in using the SCORE risk chart
† Intuitive, easy to use tool
† Takes account of the multifactorial nature of CVD
† Estimates risk of all atherosclerotic CVD, not just CHD
† Allows ﬂexibility in management—if an ideal risk
factor level cannot be achieved, total risk can still
be reduced by reducing other risk factors
† Allows a more objective assessment of risk over time
† Establishes a common language of risk for clinicians
† Shows how risk increases with age
† The new relative risk chart helps to illustrate how a
young person with a low absolute risk may be at a sub-
stantially higher and reducible relative risk.
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The SCORE risk charts are shown in Figures 2–6, including
a chart of relative risks.
The relative risk chart in Figure 6 is useful in explaining to
a younger person that, even if their absolute risk is low, it
may still be 10–12 times higher than that of a person of a
similar age with low risk factors.
Conclusions
The priorities deﬁned in this section are for clinical use and
reﬂect the fact that those at highest risk of a CVD event gain
most from preventive measures. This approach should comp-
lement public actions to reduce community risk factor levels
and promote a healthy lifestyle.
Estimation of total risk remains a crucial part of the
present guidelines. The SCORE system has been updated
with an estimate of total CVD risk as well as risk of
CVD death. New information on diabetes is included. Infor-
mation on relative as well as absolute risk is added to facili-
tate the counselling of younger persons whose low absolute
risk may conceal a substantial and modiﬁable age-related
risk.
The difﬁculty in imposing arbitrary thresholds or targets
upon a continuous variable such as risk is acknowledged.
Nevertheless, speciﬁc objectives are deﬁned in terms of
desirable levels of individual risk factors. This must be
seen as an aid to clinicians in planning risk management
strategies with their patients. The primacy of managing
total risk rather than focusing on individual risk factors is
stressed.
Priorites, risk estimation, and the deﬁnition of objectives
reﬂect an attempt to make complex issues simple and
Figure 2 SCORE chart: 10-year risk of fatal CVD in populations at high CVD risk based on the following risk factors: age, gender, smoking, systolic blood pressure,
and total cholesterol. & The European Society of Cardiology.
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Figure 3 SCORE chart: 10-year risk of fatal CVD in populations at low CVD risk based on the following risk factors: age, gender, smoking, systolic blood pressure,
and total cholesterol. & The European Society of Cardiology.
Figure 4 SCORE chart: 10-year risk of fatal CVD in populations at high CVD risk based on the following risk factors: age, gender, smoking, systolic blood pressure,
and total cholesterol:HDL cholesterol ratio. & The European Society of Cardiology.
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accessible. Their very simplicity makes them vulnerable to
criticism. Above all they must be interpreted in the light
of the physician’s detailed knowledge of their patient and
in the light of local guidance and conditions.
The ﬂow chart on p. 2389 gives a short summary of the
recommendations.
Principles of behaviour change and
management of behavioural risk factors
Scientiﬁc background
Physicians and other health professionals in the primary and
out-patient care setting are in a unique position to
contribute signiﬁcantly to the improved prevention and
management of CVD. Physicians are generally perceived by
the general public as the most reliable and credible source
of information on health and advice. Patients usually want
to receive as much information as possible from physicians,
and often prefer to receive assistance from them in order to
change behaviours such as smoking, nutrition and diet, and
physical activity, rather than attend special programmes
elsewhere.
The physician/caregiver–patient interaction as a
means towards behavioural change
A friendly and positive physician–patient interaction is a
powerful tool to enhance patients’ coping with stress and
illness and adherence to recommended lifestyle change
and medication.
Social support provided by caregivers, including phys-
icians, and shared decision making can help patients main-
tain healthy habits and adhere to medical advice.
Previous negative, unsuccessful attempts to change beha-
viour, however, often result in a lower self-efﬁcacy for
future change in that behaviour, and often lead to another
failure. A crucial step in changing negative experiences to
positive is to set realistic goals, and goal setting combined
with self-monitoring of the chosen behaviour are the main
tools to achieve a positive outcome. This in turn will
increase self-efﬁcacy for the chosen behaviour, and there-
after new goals could be set. Moving forward in small
Figure 5 SCORE chart: 10-year risk of fatal CVD in populations at low CVD risk based on the following risk factors: age, gender, smoking, systolic blood pressure,
and total cholesterol:HDL cholesterol ratio. & The European Society of Cardiology.
Figure 6 Relative risk chart. & The European Society of Cardiology.
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consecutive steps is one of the key points in long-term beha-
viour change.
Specialized and multimodal interventions
A number of specialized psychosocial intervention strategies
have been demonstrated to have positive effects on risk
factors, but the speciﬁc content and approaches taken by
these interventions vary. Even if they intend to target only
one behavioural risk factor, group-based behavioural inter-
ventions often contain elements which affect multiple risk
factors. Interventions adding psychosocial and psychoeduca-
tional components to standard cardiological care can signiﬁ-
cantly improve quality of life and diminish cardiovascular
risk factors.44–46
Practical aspects: management of behavioural
risk factors
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Smoking
Scientiﬁc background
There is overwhelming evidence for an adverse effect of
smoking on health.47 This adverse effect of smoking is
related to the amount of tobacco smoked daily and to the
duration of smoking. The effects of smoking on CVD interact
synergistically in the presence of other CVD risk factors such
as age, gender, arterial hypertension, and diabetes.
Passive smoking has been shown to increase the risk of
CHD and other smoking-related diseases.48
The beneﬁts of smoking cessation have been extensively
reported.49,50 Some of the advantages are almost immedi-
ate; others take more time. Stopping smoking after an MI
is potentially the most effective of all preventive measures.
Sufﬁcient efforts should be devoted to this end.
Practical aspects: prevention and management
of smoking
The assessment of smoking status should be done at every
opportunity.
Stopping smoking should be encouraged in all smokers.
There is no age limit to the beneﬁts of smoking cessation.
Quitting smoking is a complex and difﬁcult process,
because the habit is strongly addictive both pharmacologi-
cally and psychologically. Quitting can be facilitated with
professional assistance. The physician’s ﬁrm and explicit
advice that a person should stop smoking completely is the
most important factor in getting the smoking cessation
process started. The momentum for smoking cessation is
particularly strong at the time of diagnosing atherothrombo-
tic CVD and in connection with an invasive treatment, such
as coronary artery bypass grafting, percutaneous translum-
inal coronary angioplasty, or vascular surgery. The phys-
ician’s advice is equally important in helping healthy high
risk individuals to attempt to quit smoking. Assessing
whether the person is willing to try to quit, brief reiteration
of the cardiovascular and other health hazards of smoking,
and agreeing on a speciﬁc plan with a follow-up arrange-
ment are the decisive ﬁrst steps and essential features of
the brief initial advice of smoking cessation in clinical
practice.
Both individual and group behavioural interventions are
effective in helping smokers to quit.51 However, the
quality of physician–patient communication seems to be
more relevant than the quantity of counselling sessions
or the intervention format (group vs. individual). Support
by the partner and family is very important in smoking
cessation. Involvement of the family in the smoking
cessation process and getting other smoking family
members to quit smoking together with the patient is of
great help.
Nicotine chewing gum and transdermal nicotine
patches have been widely used in helping quitters to go
through the difﬁcult initial weeks or months of smoking
cessation.
Antidepressant medication in aiding long-term smoking
cessation has been shown to be effective. Bupropion and
nortriptyline can aid smoking cessation.
Another new pharmacological agent that may be of help
in smoking cessation is varenicline, a nicotine acetylcholine
receptor agonist. Among long-term smokers, treatment
with varenicline was associated with a smoking cessation
rate of 23% at 1 year as compared with 15 and 10.3% in
the groups treated with buproprion and placebo, respect-
ively. Reports that it may be more effective than bupro-
prion or placebo need conﬁrmation.
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Nutrition
Scientiﬁc background
Fatty acids regulate cholesterol homeostasis and concen-
trations of blood lipoproteins, and affect the levels of
other cardiovascular risk factors, such as BP, haemostasis,
and body weight, through various mechanisms. There are
strong, consistent, and graded relationships between satu-
rated fat intake, blood cholesterol levels, and the mass
occurrence of CVD. The relationships are accepted as
causal. n-3 fatty acids, in contrast, showed protective
effects on fatal events in patients who had suffered a pre-
vious MI. Sodium intake, especially in the form of sodium
chloride, inﬂuences arterial BP and therefore the risk of
arterial hypertension, stroke, CHD, and heart failure.
Intervention trials with vitamin supplements have failed
to demonstrate any protection against CHD. Besides
micro- and macronutrients, dietary patterns, including
fruit and vegetables, monounsaturated fatty acid-rich oil
(such as olive oil), and low fat dairy products, have been
associated with decreased incidence of cardiovascular
events.
Practical aspects: management
Dietetics is an integral part of cardiovascular patient risk
management. All patients having a CVD and those individ-
uals at high risk should be given professional advise on the
food and dietary options which reduce the cardiovascular
risk. A varied and energy-balanced regimen together with
regular exercise is critical to the preservation of a good car-
diovascular health.
Dietetic recommendations should be deﬁned individually,
taking into account the subject’s risk factors—dyslipidaemia,
hypertension, diabetes, and obesity.
Overweight and obesity
Scientiﬁc background
As societies develop a higher standard of living, cardiovas-
cular mortality initially increases. This is followed by a
reduction in both major risk factors such as blood choles-
terol and high BP which, together with improvements in
therapy, translate into reduced cardiovascular mortality.
The exceptions to these trends are body weight and dia-
betes which tend to increase as other risk factors decline.
Obesity is becoming a worldwide epidemic in both children
and adults.52 Currently it is estimated that, worldwide,
over 1 billion people are overweight, and over 300 million
are obese. Over one-third of children are overweight or
obese.
Body weight and risk
It is now clear that fat, and in particular intra-abdominal
visceral fat, is a metabolically active endocrine organ that
is capable of synthesizing and releasing into the bloodstream
an important variety of peptides and non-peptide com-
pounds that may play a role in cardiovascular homeostasis.
Fat is associated with increased secretion of free fatty
acids, hyperinsulinaemia, insulin resistance, hypertension,
and dyslipidaemia.53,54 This impacts on CVD risk factors
and hence on risk. The mechanical effects of overweight
impact on non-cardiovascular causes of morbidity and mor-
tality. The health effects of increasing body weight are sum-
marized in Table 3.
Interestingly, the effects of multivariate adjustment
on the association between lipid levels and risk and
between body weight and risk are different. Raised blood
cholesterol or a reduced HDL cholesterol level remain inde-
pendently associated with risk after adjustment for other
major risk factors, whereas the association between
weight and risk tends to lose signiﬁcance. This should
not be interpreted as indicating that body weight is not
important; rather, it may be critically important because it
exerts its effect on risk by its adverse effects on many risk
factors.
Table 3 Impact of increasing body weight on risk factors, morbidity,
and mortality
Risk factors Morbidity Mortality
Raised BP
Raised total and LDL
cholesterol
Reduced HDL
cholesterol
Increased waist
circumference
Sleep apnoea
Obesity hypoventilation
syndrome
Physical inactivity
Type 2 diabetes
Insulin resistance
Coronary heart disease
Stroke
Osteoarthritis (knee)
Cancer
Low back pain due to
obesity
Breathlessness
Polycystic ovary
syndrome
Infertility
Cholelithiasis
Asthma (exacerbation)
Venous
thromboembolic
pulmonary
embolism
Inﬂammation
Autonomic nervous
system dysfunction
Increased total
and cardiovascular
mortality
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Which index of obesity is the best predictor of
cardiovascular risk and cardiovascular risk
factors—body mass index (BMI), waist
circumference (WC), or waist–hip circumference
ratio (WHR)?
Recent studies have demonstrated that regional distribution
of adipose tissue may be more important in determining
cardiovascular risk than total body weight. Excess central
(visceral abdominal) fat in particular has been shown to be
strongly associated with metabolic and cardiovascular
risk.55 This has led to increased interest in anthropometric
measures of risk. Most data are available for BMI, waist–hip
circumference ratio (WHR), and, more recently, simple
waist circumference (WC). Such measures of risk are cheap
and universally available. WC, while simple, may be more
prone to measurement error than BMI. The optimal level
for measurement of WC is midway from the lower rib
margin to the anterior superior iliac crest. The evidence sup-
porting each measure in estimating risk is now considered.
BMI has been extensively used to deﬁne the groups of body
weight [kg/height (m)2] using classiﬁcations suggested by
the National Institutes of Health and the WHO. In adults,
overweight is deﬁned by an increased BMI ranging from 25
to 29.9 kg/m2 and obesity by BMI 30 kg/m2. Increasing
BMI is highly associated with CVD.
The association between both increasing WC and WHR and
greater risk of development of CVD has been demonstrated
in cohort and case–control studies.56 In general, these
have shown that the measurement of WC in addition to
BMI gives additional information for CVD risk estimation.
The association between increasing WC or WHR and the pre-
sence of other cardiovascular risk factors or the metabolic
syndrome has been shown in many cross-sectional
studies.57 There is no consistent information on which of
these anthropometric measures is superior.
Both theWHO report on obesity58 and the American National
Heart, Lung, and Blood Institute (NHLBI) expert panel on
obesity59 recommend the use of WC as an additional indicator
of metabolic risk factors, within each category of BMI. Of
various deﬁnitions,58,59 the WHO cut-off points are the most
widely accepted in Europe; two action levels are rec-
ommended. Action level 1—WC 94 cm in men and 80 cm
in women—represents the threshold at which no further
weight should be gained. Action level 2—WC 102 cm in men
and 88 cm in women represents the threshold at which
weight reduction should be advised. The cut-off points have
been calculated based on white people, and it is apparent
thatdifferent cut-off points for anthropometricmeasurements
are required in different races and ethnicities.60
In conclusion, there is no solid evidence for superiority of
either variable in the prediction of risk factors. WC has the
advantage of simplicity, may be a slightly better estimator
of risk than BMI, but is probably more prone to measurement
error.
Imaging and fat distribution
Several measurements have been described for assessing the
anatomical distribution of fat, such as computed tomogra-
phy (CT), ultrasound (US), and magnetic resonance
imaging (MRI). They allow changes in intra-abdominal
fat to be monitored. However, they are expensive and
time consuming, and are to be regarded as specialist
research tools rather than everyday risk assessment tools
at this time.
Anthropometric measurements such as WC and WHR
provide a useful estimation of the proportion of abdominal
or upper-body fat, but they do not distinguish between
accumulations of deep abdominal (visceral) fat and subcu-
taneous abdominal fat. CT can be considered the gold stan-
dard not only for adipose tissue evaluation but also for
multicompartment body measurement;61 the subcompart-
ments of adipose tissue volume, visceral and subcutaneous
adipose tissue, can be accurately measured with errors of
1.2 and 0.5%, respectively.
MRI provides results similar to CT without exposure to
ionizing radiation, the main problem with CT multislice
measurements. It demonstrates good reproducibility for
total and visceral adipose tissue volumes.62
Several studies demonstrated a highly signiﬁcant corre-
lation between the intra-abdominal adipose tissue deter-
mined by CT and by US.63,64
Sagittal abdominal diameter is derived either from a CT
abdominal scan65 or by using a sagittometer placed over
the abdomen perpendicular to the length axis of the trunk
at the iliac crest level (L4–5) with the subject in the
supine position on a ﬁrm bench with the knees bent.66 Sagit-
tal abdominal diameter correlates strongly with visceral fat
volume as measured by CT.67 CT scanning is expensive and
involves exposure to radiation. It is not as yet recommended
for routine clinical risk assessment.
Practical aspects: management of obesity
and overweight
Intentional weight loss in obese patients can improve or
prevent many of the obesity-related risk factors for CHD.
Reduction in BP occurs before attainment of desirable
body weight.
Physical activity and body weight
There is sufﬁcient evidence available from intervention
studies supporting the role of physical activity and moderate
to vigorous exercise in promoting weight loss.68 Recent
research has indicated that exercise may have beneﬁcial
effects before a training effect is apparent69,70 and may
impact on abdominal fat metabolism before weight loss
occurs.69,70 This information may be valuable in motivating
high risk persons to initiate exercise.
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Diet and behavioural interventions
Many different diets and behavioural interventions have been
proposed for the treatment of obesity. The control of over-
weight is dependent upon achieving the appropriate
balance between energy intake and expenditure. The
dietary approaches vary in their total energy content, macro-
nutrient composition (protein, carbohydrates, and lipids),
energy density, and glycaemic index.71 The low fat diet is
considered the standard approach to weight reduction and
has a more favourable effect on LDL cholesterol. Total fat
intake should be kept between 25 and 35% of energy. The
reduction in saturated fats is the preferred target due to its
effects on the lipoprotein proﬁle. Intake of saturated and
trans fatty acids should be ,7%.72
The low carbohydrate diet has become popular and in the
short term decreases body weight greatly and also has a
good effect on plasma triglycerides and HDL cholesterol.73
However, its long-term safety is still under investigation.
Alcohol is a major source of calories and reduction may be
an important part of weight control.
Behaviour modiﬁcation inducing long-term lifestyle
change leading to a gradual weight loss is the basis of all
obesity treatment. According to a recent Cochrane review,
behavioural and cognitive–behavioural therapy helps to
lose additional weight when added to diet and exercise pro-
grammes.74 Behavioural interventions have also been shown
to help maintain weight loss.75
Drug treatment of overweight
In general, the contribution of drug treatments is modest
and, in the past, some products have had serious side effects.
Orlistat inhibits intestinal lipases to prevent the hydrolysis
and uptake of fat. Weight loss is usually modest, and gastro-
intestinal disturbance may occur. It should be used with a
full and balanced diet.
Sibutramine enhances a feeling of satiety after food by an
effect of its metabolites which inhibit noradrenaline and
serotonin uptake. Both contraindications and side effects
are appreciable.
Rimonabant is an endocannabinoid receptor inhibitor that
appears capable of inducing a modest but sustained weight
loss in combination with a calorie-controlled diet. It may
improve glucose tolerance, beneﬁcially affect lipid metab-
olism, and is associated with a modest reduction in BP. Poss-
ible adverse effects on depression are being monitored. It
remains to be seen if its promising effects on weight and
other risk factors will translate into hard evidence of
reduced cardiovascular events.
Physical activity
Scientiﬁc background
† A lack of regular physical activity may contribute to the
early onset and progression of CVD.
† Almost any increase in physical activity will result in
health beneﬁts.
† Assessment of physical activity is a key element of risk
evaluation.
Physical inactivity is a signiﬁcant public health problem in
Europe: children have become less physically active and
only in a few countries do children have access to the
recommended daily dose of physical activity. More than half
of adolescents become physically inactive after leaving
school.
Adults face a signiﬁcant decrease in physical demands at
their place of work and, during leisure time, fewer people
are physically active. A sedentary lifestyle is associated
with a doubling of the risk of premature death and with an
increased risk of CVD.76,77 Avoiding a sedentary lifestyle
during adulthood may extend total life expectancy and
CVD-free life expectancy (by 1.3–3.5 years).78
Physical training has a wide variety of beneﬁcial effects on
the course of atherosclerosis, resulting in a 20–25%
reduction in overall mortality.79 Yet, in Europe, a minority
of CVD patients participate in exercise training programmes.
Even fewer patients with chronic heart failure (CHF) are
enrolled, although they may well beneﬁt from adapted exer-
cise training.
In the elderly population, approximately a quarter of the
population suffer from CVD. Physiological and mental
changes that come with increasing age may contribute
to physical inactivity, but regular physical activity may
effectively slow down the age-related changes, thereby
improving physical functioning and extending disease-free
survival.
Estimating physical activity
For an assessment of physical activity, different methods
are available: doubly labelled water, indirect calorimetry,
direct observation, activity monitors (pedometers, acceler-
ometers), heart rate monitors and questionnaires, or activity
diaries. For physical ﬁtness and exercise capacity, maximal
incremental exercise testing is used.80
In clinical practice, the assessment should be combinedwith
a total CVD risk estimation using the SCORE/HeartScore
method. In individuals at low risk, a brief interview concerning
the person’s physical activity may sufﬁce, but in high risk
persons this may be completed with an exercise test. Assess-
ment in adults with known CVD should be combined with exer-
cise testing in order to detect myocardial ischaemia, stratify
for risk, and give guidance on the clinical management.
Practical aspects: management
In the young population, the promotion of physical ﬁtness is
the shared responsibility of parents, school staff, health
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care providers, politicians, and society as a whole: each
child in Europe should have access to periods of physical
activity each day. Here, more research is needed to ﬁnd
instruments for measuring physical ﬁtness and activity, and
to create programmes to improve and maintain physical
activity.
The choice of lifestyle, including maintained physical
ﬁtness, remains the sole responsibility of the individual
person. This may be supported by family and friends, work
environment, access to attractive and affordable leisure
time activities, and by health-promoting campaigns.
Regular physical exercise within the resources of the work
place is recommended. The ultimate goal is at least half
an hour of physical activity on most days of the week as
almost any increase in activity is associated with measurable
health beneﬁts.
The intensity may be deﬁned in terms of target heart rate
or perceived exertion. A heart rate during peak exercise of
60–75% of the average maximum heart rate is preferred.
The Borg scale of perceived exertion may be applied,
using the level of ‘moderate exertion’. This may be easily
achieved by a wide variety of activities such as brisk
walking or jogging, cycling, swimming, gardening, aerobic
dancing, tennis, golf, or even cross-country skiing.81
Recommendations for patients with known CVD have to be
based on a comprehensive clinical judgement including
exercise testing. A majority will beneﬁt from a cardiac reha-
bilitation programme: in addition to supervised physical
exercise in patient groups, this includes lifestyle advice
and support as well as measures aimed at risk reduction. If
patients prefer to perform the programme at home, they
will need clear prescriptions, encouragement, and regular
follow-up by their physician. For patients with mild to mod-
erate heart failure, both dynamic interval training with
moderate intensity and resistance training may be
advantageous.
When counselling elderly persons, it is recommended to
maintain daily physical activity on a moderate to submaxi-
mum level. Principles of behavioural change including
social support, self-efﬁcacy, and positive reinforcement
should be applied, and programmes should start off at low
intensity but gradually increase to moderate levels. Key
elements of activity programmes for the elderly are a com-
bination of endurance, strength, balance, and ﬂexibility.
Even the elderly CVD patient may beneﬁt from rehabilita-
tion programmes: exercise training is safe, improves
strength, aerobic ﬁtness, endurance, and physical function,
and there are no gender differences in the outcome.
Thus, the assessment, counselling, and support in the
maintenance of physical activity are core tasks for phys-
icians and other health workers engaged in the prevention
of cardiovascular disease.
Heart rate
Scientiﬁc background
Elevated heart rate has been shown to be associated
with increased risk of all-cause mortality, CVD mortality,
and development of CVD in the general population, hyper-
tensives, diabetics, and those with pre-existing coronary
artery disease.82,83 The relationship is also seen in animal
models. Levine demonstrated the semi-logarithmic inverse
relationship between heart rate and life expectancy in
mammalian species.84 A reduction in the development of
atherosclerosis has been demonstrated in cholesterol-fed
monkeys after pharmacological or surgical reduction of
heart rate.85
Most epidemiological studies have shown the relationship
to be strong, graded, and independent of other factors
including BP and physical activity. While virtually all of the
studies demonstrated a signiﬁcant effect in men, the
relationship between CVD mortality and elevated heart
rate in women and the elderly was non-signiﬁcant after
multivariate adjustment in some of the studies. Risk of
sudden death in men is particularly associated with elevated
resting heart rate.86
A low heart rate may be exerting its effect on CVD through
anti-arrhythmic or anti-ischaemic effects. Other possible
mechanisms are the direct effect on haemostatis of an elev-
ated heart rate causing progression of atherosclerosis.
No trial has investigated the effect of lowering heart rate
on prognosis in asymptomatic people. Meta-analyses of
b-blocker and calcium channel blocker therapy in post-MI
patients and in CHF have demonstrated their beneﬁts in
these patients.87,88 Studies have shown that the beneﬁt
achieved is related to the level of heart rate reduction;
however, it is uncertain if this is the only mechanism in
the beneﬁt of b-blockade.89
Practical aspects: management
In the general population, avoidance of elevated heart rate
through lifestyle measures can be recommended. These
include regular physical activity, avoidance of psychological
stress, and excessive use of stimulants such as caffeine.
Pharmacological reduction of heart rate cannot be rec-
ommended in the asymptomatic population.
Both b-blockers and selective If channel blockers are
effective in the treatment of angina.90 b-Blockers are rec-
ommended in patients post-MI and in CHF patients in care-
fully titrated doses.
Blood pressure
Scientiﬁc background
Elevated BP is a risk factor for CHD91, heart failure, CVD,
peripheral vascular disease, and renal failure in both men
and women.91–94 BP levels correlate inversely with cognitive
function, and hypertension is associated with an increased
incidence of dementia.95 CHD and stroke mortality increase
progressively and linearly from BP levels as low as 115 mmHg
systolic and 75 mmHg diastolic upward.96
In addition, longitudinal data obtained from the Framing-
ham Heart Study indicated that BP values in the 130–139/
85–89 mmHg range are associated with a .2-fold increase
in relative risk from CVD compared with those with BP
levels below 120/80 mmHg.97
The classiﬁcation of hypertension used in the 2003 and
2007 ESH/ESC guidelines has been retained (Table 4). Iso-
lated systolic hypertension should be graded as the same
as the systolic BP values indicated for systolic–diastolic
hypertension. However, the association with a low diastolic
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BP (e.g. 60–70 mmHg), indicating a wide pulse pressure,
should be regarded as higher risk.
Risk stratiﬁcation and target organ damage
The decision to start pharmacological treatment depends
not only on the BP level but also on total cardiovascular
risk, which calls for a careful history, physical examination,
and laboratory tests to identify (i) the presence of clinically
established CVD; (ii) the co-existence of other cardiovascu-
lar risk factors; and (iii) the presence of subclinical CVD or
end-organ damage—an intermediate stage in the continuum
of cardiovascular risk. The presence of clinically established
cardiovascular or renal disease markedly increases the risk
of subsequent cardiovascular events at all levels of BP
(Table 5).
The co-existence of other cardiovascular risk factors
(smoking, increased plasma cholesterol, family history of
Table 4 Deﬁnition and classiﬁcation of blood pressure levels
Category Systolic Diastolic
Optimal ,120 and ,80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 2 hypertension 160–179 and/or 100–109
Grade 3 hypertension 180 and/or 110
Isolated systolic hypertension 140 and ,90
Isolated systolic hypertension should be graded (1, 2, 3) according to
systolic blood pressure values in the ranges indicated, provided that dias-
tolic values are ,90 mmHg. Grades 1, 2, and 3 correspond to classiﬁ-
cation of mild, moderate, and severe hypertension, respectively. These
terms have now been omitted to avoid confusion with quantiﬁcation of
total cardiovascular risk.
Table 5 Factors inﬂuencing prognosis in hypertension
Risk factors Target organ damage Diabetes mellitus Established CVD or real disease
† Systolic and diastolic BP levels † Electrocardiographic LVH
(Sokolow–Lyons . 38 mm;
Cornell . 2440 mm  ms)
† Fasting plasma
glucose  7.0 mmol/L
(126 mg/dL)
† Cerebrovascular disease:
ischaemic stroke; cerebral
haemorrhage; transient
ischaemic attack
or:
† Levels of pulse pressure (in the
elderly)
† Age (M . 55 years; W . 65 years) or: † Postload plasma
glucose .110 mmol/L
(198 mg/dL
† Smoking † Echocardiographic LVHa
(LVMI M 125 g/m2,
W  110 g/m2)
† Dyslipidaemia † Heart disease: myocardial
infarction; angina;coronary
revascularization; heart failure
– TC. 5.0 mmol/L (190 mg/dL) † Carotid—wall thickening
(IMT 0.9 mm)
or: or plaque
– LDL-C . 3.0 mmol/L(115 mg/dL) † Carotid–femoral pulse
wave velocity .12 m/s
or:
– HDL-C: M, 1.0 mmol/L (40 mg/dL),
W, 1.2 mmol/L (46 mg/dL) † Ankle/brachial BP
index , 0.9
† Renal disease: diabetic
nephropathy; renal impairment
(serum creatinine M. 133,
W . 124 mmol/L) proteinuria
(.300 mg/24 h)
or:
– TG. 1.7 mmol/L (150 mg/dL) † Slight increase in plasma
creatinine:
M: 115–133 mmol/L
(1.3–1.5 mg/dL);
† Fasting plasma glucose
5.6–6.9 mmol/L (100–125 mg/dL)
W: 107–124 mmol/L
(1.2–1.4 mg/dL)
† Abnormal glucose tolerance test † Low estimated glomerular
ﬁltration rateb
(,60 mL min/1.73 m2) or
† Abdominal obesity [waist
circumference .102 cm (M), .88 cm
(W)]
creatinine clearancec
(, 60 mL/min)
† Peripheral artery disease
† Family history of premature CV
disease (M at age , 55 years; W at
age , 65 years)
† Microalbuminuria 30–
300 mg/24 h or albumin
creatinine ratio:  22 (M);
or 31 W) mg/g creatinine
† Advanced retinopathy:
haemorrhages or exudates,
papilloedema
The cluster of three out of ﬁve factors among abdominal obesity, fasting blood glucose, BP 140/85 mmHg, low HDL cholesterol (M, ,40 mg/dL or
1.03 mmol/L; W, ,50 mg/dL or 1.29 mmol/L, and high triglycerides (150 mg/dL or 1.7 mmol/L) indicates the presence of a metabolic syndrome.
M ¼ men; W ¼ women; CVD ¼ cardiovascular disease; IMT ¼ intima-media thickness.
aRisk maximal for concentric LVH (left ventricular hypertrophy):increased LVMI (left ventricular mass index) with a wall thickness/radius ratio 0.42.
bMDRD formula.
cCockroft–Gault formula.
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premature CVD) also greatly adds to the risk associated with
a mild BP elevation (see SCORE risk charts).42
Practical aspects: management of hypertension
Who to treat?
The term ‘treatment’ should be taken to mean total man-
agement. This means detailed lifestyle advice for all those
with raised BP, with the judicious use of medication in
some. The decision to start antihypertensive drug treatment
depends on the presence or absence of established CVD, dia-
betes, renal disease, target organ damage, and, of critical
importance in all other persons, on the SCORE estimate of
total CVD risk (Table 6), Persons in whom repeated BP
measurements show grade 2 or 3 hypertension (i.e. systolic
values 160 mmHg or diastolic values 100 mmHg) are gen-
erally regarded as candidates for antihypertensive treat-
ment because a large number of placebo-controlled trials
have conclusively demonstrated that, in patients with
these BP values, BP reduction lowers cardiovascular morbid-
ity and mortality98–101. However, the beneﬁt may be modest
in those at low total CVD risk. In particular, randomized con-
trolled trial data are lacking to provide guidance with regard
to drug treatment in, for example, younger women without
other risk factors. The likely beneﬁts of drug treatment
should be weighed against side effects, cost, the use of
medical resources, and turning healthy people into
‘patients’.
In all grade 1–3 hypertensives, comprehensive risk factor
assessment and appropriate lifestyle counselling should be
provided after hypertension is diagnosed, while promptness
in the initiation of pharmacological therapy depends on
the level of total cardiovascular risk. Drug treatment
should be initiated promptly in grade 3 hypertension, as
well as in grade 1 and grade 2 hypertensives with increased
or markedly increased total cardiovascular risk (i.e. in
hypertensive patients with established CVD or renal
disease, TOD, diabetes, or a SCORE risk of 5%). In grade
1 or 2 hypertensives with moderate total cardiovascular
risk, drug treatment may be delayed for some time to
allow evaluation of the effects of lifestyle advice on total
risk.. However, even in these patients, lack of BP control
after a suitable period of non-pharmacological measures
should lead to instituting drug treatment in addition to life-
style measures.
When initial BP is within the high normal range (130–139/
85–89 mmHg), the decision on drug intervention depends
heavily on total cardiovascular risk. In the case of diabetes
or a history of cerebrovascular or coronary disease, evi-
dence102–110 justiﬁes the recommendation to start antihy-
pertensive drug administration (together with intense
lifestyle changes) even in patients with BP in the high
normal range, with associated CVD or diabetes.
How to treat?
Lifestyle interventions include: weight reduction in over-
weight/obese individuals; reduction in the use of sodium
chloride to ,3.8 g/day (sodium intake ,1.5 g/day, i.e.
65 mmol/day);111 restriction of alcohol consumption to no
more than 10–30 g of ethanol per day in men (1–3 standard
measures of spirits, 1–3 glasses of wine, or 1–3 bottles of
beer), and to no more than 10–20 g of ethanol per day in
women (1–2 of these drinks/day); and regular physical
activity in sedentary individuals. Hypertensives should be
generally advised to eat more fruit and vegetables (4–5 ser-
vings per day, i.e. 300 g)112 and to reduce intake of satu-
rated fat and cholesterol.
Antihypertensive drugs
The large number of randomized trials of antihypertensive
therapy, both those comparing active treatment vs.
Table 6 Management of total CVD risk—blood pressure
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placebo, and those comparing treatment regimens based on
different compounds, conﬁrm that (i) the main beneﬁts
of antihypertensive treatment are due to lowering of BP
per se, and are largely independent of the drugs employed;
and (ii) thiazide diuretics (chlorthalidone and indapamide),
b-blockers, calcium antagonists, ACE inhibitors, and angio-
tensin receptor antagonists can adequately lower BP, and
signiﬁcantly reduce cardiovascular morbidity and mortality.
These drugs are thus all suitable for initiation and mainten-
ance of antihypertensive treatment, either as monotherapy
or in combination.
Two recent large-scale trials113–115 and a meta-analysis116
have concluded that b-blockers may have a reduced ability
to protect against stroke, though being equally effective in
reducing coronary events and mortality. Moreover, adminis-
tration of b-blockers has been proven beneﬁcial in patients
with angina, heart failure, and a recent MI.87,117,118 Thus,
b-blockers should still be considered a valid option for
initial and subsequent antihypertensive treatment strat-
egies. However, they may induce weight gain,119 have
adverse effects on lipid metabolism,115 and increase (com-
pared with other drugs) the incidence of new-onset dia-
betes.120 While these effects are modest, they may
indicate caution in hypertensives with multiple metabolic
risk factors including the metabolic syndrome and its
major components.121,122 This applies also to thiazide diure-
tics, which have dyslipidaemic and diabetogenic effects,
particularly when used at high doses.120 Thiazides have
often been administered together with b-blockers in trials
showing a relative excess of new-onset diabetes, thus
making a distinction between the contributions of the two
agents difﬁcult to dissociate. These metabolic effects may
be less with vasodilating b-blockers.123,124
Trials assessing intermediate end-points suggest other
differences between various antihypertensive agents or
compounds: ACE inhibitors and angiotensin receptor antag-
onists have been reported to be particularly effective in
reducing left ventricular hypertrophy,125 including the ﬁbro-
tic component,126,127 and microalbuminuria and protei-
nuria,106,128–130 and in preserving renal function and
delaying end-stage renal disease.130–133 Calcium antagon-
ists, beside being effective on left ventricular hypertrophy,
appear particularly beneﬁcial in slowing down progression
of carotid hypertrophy and atherosclerosis.134–136 Evidence
concerning the beneﬁts of other classes of antihypertensive
agents is much more limited.
Combination treatment is frequently needed to control
BP.137 Drugs that have a long-lasting effect and a documen-
ted ability to lower BP effectively over 24 h with once-a-day
administration are preferred. Simpliﬁcation of treatment
improves adherence to therapy,138 while effective 24 h BP
control is prognostically important in addition to ofﬁce
blood pressure control.139 Long-acting drugs also minimize
BP variability and this may offer protection against pro-
gression of target organ damage and risk of cardiovascular
events.140–142
Desirable blood pressure
The primary goal of treatment of the hypertensive patient is
to achieve the maximum reduction in the long-term total
risk of cardiovascular morbidity and mortality. This requires
treatment of all the reversible risk factors identiﬁed,
including smoking, dyslipidaemia, or diabetes, and the
appropriate management of associated clinical conditions,
as well as treatment of the elevated BP per se.
If possible, BP should be reduced to below 140/90 mmHg
in all hypertensive patients who qualify for drug treatment
and lower if lack of side effects permits. In diabetic
patients, antihypertensive treatment should be more
intense, and a goal of ,130/80 mmHg has been proposed.
The same target is appropriate for subjects with established
cardiovascular disease if feasible.
Duration of treatment
Generally, antihypertensive therapy should be maintained
indeﬁnitely. In general clinical practice, hypertension is
not well treated and only a minority of subjects achieve a
BP of ,140/90 mmHg.143 Increasing compliance with antihy-
pertensive treatment and achieving a wide BP control in the
population thus represents a major challenge for clinical
practice in the future.
Plasma lipids
Scientiﬁc background
The relationship between a raised plasma cholesterol and
atherosclerotic vascular disease fulﬁls all of the criteria
for causality. The evidence that reducing plasma cholesterol
reduces risk is equally unequivocal. The higher the risk, the
greater the beneﬁt. A 10% reduction in plasma total choles-
terol is followed by a 25% reduction in incidence of coronary
artery disease after 5 years, and a reduction of LDL choles-
terol of 1 mmol/L (40 mg/dL) is accompanied by a 20%
reduction in CHD events.144 While the relationship
between a reduced HDL cholesterol level and risk is
strong, trial data do not yet permit the deﬁnition of a
target level for HDL cholesterol. Raised plasma triglycerides
signal the need to look for those other factors that may be
associated with the so-called metabolic syndrome.
Practical aspects: management
As with raised BP, the ﬁrst principle of management is to
assess and control all components of total CVD risk by
means of appropriate advice with regard to smoking, exer-
cise, nutrition, and BP control.
In general, total plasma cholesterol should be below
5 mmol/L (190 mg/dL), and LDL cholesterol should be
below 3 mmol/L (115 mg/dL). In the highest risk subjects,
especially those with clinically established atheros-
clerotic CVD and patients with diabetes, the treatment
goals should be lower: total cholesterol ,4.5 mmol/L
(175 mg/dL) with an option of ,4 mmol/L (155 mg/dL)
if feasible, and LDL cholesterol ,2.5 mmol/L (100 mg/
dL) with an option of ,2 mmol/L (80 mg/dL) if feasible.
If these targets are not feasible, total risk can still be
reduced by means of increased efforts to control other risk
factors.
Should statins be given to all persons with
cardiovascular disease?
Relative risk reductions seem to be constant at all lipid
levels, but absolute risk reductions are small in those with
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low lipid levels, with little evidence of a reduction in total
mortality. The universal use of statins may be unrealistic
in some economies.
No speciﬁc treatment goals are deﬁned for HDL choles-
terol and triglycerides, but concentrations of HDL choles-
terol ,1.0 mmol/L (40 mg/dL) in men and ,1.2 mmol/L
(45 mg/dL) in women, and, similarly, fasting triglycerides
.1.7 mmol/L (150 mg/dL), serve as markers of increased
cardiovascular risk. Values of HDL cholesterol and triglycer-
ides should also be used to guide the choice of drug therapy.
Asymptomatic people at high multifactorial risk of develop-
ing CVD, whose untreated values of total and LDL cholesterol
are already close to 5 and 3 mmol/L, respectively, seem to
beneﬁt from further reduction of total cholesterol to
,4.5 mmol/L (175 mg/dL) and, if feasible, lower, and from
further reduction of LDL cholesterol to ,2.5 mmol/L
(100 mg/dL) and, if feasible, lower, with lipid-lowering drugs.
Table 7 summarizes the management of plasma lipids in
clinical practice. The ﬁrst step is to assess total cardiovascu-
lar risk and to identify these components of risk that are to
be modiﬁed. If the 10-year risk of cardiovascular death is
,5% and will not exceed 5% if the individual’s risk factor
combination is projected to age 60, professional advice on
diet, regular physical activity, and stopping smoking should
be given to keep the cardiovascular risk low. Risk assessment
should be repeated at 5-year intervals.
Note that assessment of total risk does not pertain to
patients with familial hypercholesterolaemia, since total
cholesterol .8 mmol/L (320 mg/dL) and LDL cholesterol
.6 mmol/L (240 mg/dL) by deﬁnition places a patient at
high total risk of CVD, especialy as the raised cholesterol
level will have been present since childhood. This high risk
justiﬁes lipid-lowering therapy even in young asymptomatic
subjects.
If the 10-year risk of cardiovascular death is 5%, or will
become 5% if the individual’s risk factor combination is
projected to age 60, a full analysis of plasma lipoproteins
(total cholesterol, LDL cholesterol, HDL cholesterol, and tri-
glycerides) should be performed, and intensive lifestyle
advice, particularly dietary and physical activity advice,
should be given. If values of total and LDL cholesterol fall
below 5 mmol/L (190 mg/dL) and 3 mmol/L (115 mg/
dL), respectively, and the total CVD risk estimate has
become ,5%, then these persons should be followed at
yearly intervals to ensure that cardiovascular risk remains
low without drugs. In contrast, if total CVD risk remains
5%, lipid-lowering drug therapy should be considered to
lower total and LDL cholesterol even further. The goals in
such persistently high risk individuals are to lower total
cholesterol to ,4.5 mmol/L (175 mg/dL) with an option
of ,4 mmol/L (155 mg/dL) if feasible, and to lower LDL
cholesterol to ,2.5 mmol/L (100 mg/dL) with an option
of ,2 mmol/L (80 mg/dL) if feasible. As stated earlier,
these lower values are not goals of therapy for patients
with higher untreated values. It has to be stressed that
the beneﬁts of cholesterol-lowering therapy depend on
initial levels of risk: the higher the risk, the greater the
beneﬁt.
Since the lifelong CVD risk in diabetic patients may be as
high as in non-diabetic individuals with prior CVD, particu-
larly if they have some other risk factors or have microalbu-
minuria, earlier and intensive prevention using
lipid-lowering drugs, even in type 2 diabetic patients with
moderate risk, is needed.145,146
Table 7 Management of total CVD risk—lipids
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Despite early observational studies indicating that plasma
cholesterol is not associated with overall rates of stroke, and
that lowering cholesterol does not lower the risk of stroke,
most of the large statin trials reported signiﬁcant reductions
in stroke rates in patients with or at high risk of getting cor-
onary artery disease147–149 due to a reduction in the rates of
ischaemic stroke.150 Therefore, the patients with cerebro-
vascular disease as well as the patients with PAD merit the
same degree of attention to treatment of plasma lipids as
patients with coronary artery disease.
In all patients with an acute coronary syndrome, statin
treatment should be initiated while the patients are in the
hospital.151–153 Such early drug treatment should neverthe-
less be combined with effective lifestyle changes and par-
ticularly dietary intervention after hospital discharge.
The beneﬁts of statins appear to apply to both genders
and most ages,145 although the beneﬁts in healthy, asympto-
matic women are not proven.
The current armamentarium of lipid-lowering drugs
includes inhibitors of hydroxy-3-methyl-glutaryl-CoA
reductase (statins), ﬁbrates, bile acid sequestrants (anion
exchange resins), niacin (nicotinic acid), and selective
cholesterol absorption inhibitors (e.g. ezetimibe). Statins
have been shown not only to reduce hyperlipidaemia but
also to reduce cardiovascular events and mortality as well
as the need for coronary artery by-pass grafting and
various forms of coronary angioplasty. Statins in the
highest doses seem also to halt progression or induce
regression of coronary atherosclerosis.105,154 Therefore,
they should be used as the drugs of ﬁrst choice. These
drugs are easy to use and all have proved safe in large
trials.144. Liver dysfunction is occasional and reversible.
Rhabdomyolysis is rare; severe muscle pain requires
immediate cessation of therapy. Because statins are pre-
scribed on a long-term basis, possible interactions with
other drugs (ciclosporin, macrolides, azole antifungals,
calcium antagonists, protease inhibitors, sildenaﬁl, war-
farin, digoxin, nicotinic acid, ﬁbrates, etc.) deserve particu-
lar attention, as many patients will receive pharmacological
therapy for concomitant conditions during the course of
statin treatment.155
Selective cholesterol absorption inhibitors can be used in
combination with statins in patients not reaching treatment
goals with statins. Bile acid sequestrants also decrease total
and LDL cholesterol, but tend to increase triglycerides.
Fibrates and nicotinic acid are used primarily for triglyceride
lowering and increasing HDL cholesterol, while ﬁsh oils
(omega-3 fatty acids) are used for triglyceride lowering.
In some patients, combination therapy with different
lipid-lowering drugs is necessary to achieve the treatment
goals. The combination of statins with ﬁbrates has been
associated with a moderately higher likelihod of myopathy
and occasional rhabdomyolysis. Therefore, patients must
be carefully selected and carefully instructed about
warning symptoms. However, these adverse effects are
very rare and should not be the reason to deny the combined
treatment to patients who really need it.
In some patients, goals cannot be reached even on
maximal lipid-lowering therapy, but they will still beneﬁt
from treatment to the extent to which cholesterol has
been lowered. Increased attention to other risk factors
offers an additional way to reduce total risk.
Diabetes
Scientiﬁc background
The extensive literature on diabetes and its precursor stages
and CVD has been thoroughly reviewed in the recent guide-
lines on diabetes, pre-diabetes and cardiovascular disease
created by the Joint Task Force of the ESC and the European
Association for the Study of Diabetes. In addition to the full
text of the present guideines, the readers are referred to
that document.5
Practical aspects: management
In subjects with impaired glucose tolerance, it has been
demonstrated that progression to diabetes can be prevented
or delayed by lifestyle intervention. Even temporary inter-
ventions seem to have a long-lasting impact years after
the intervention period.
In patients with type 1 diabetes as well as with type 2 dia-
betes, randomizedtrials consistently showthatgoodmetabolic
control prevents microvascular complications. In relation to
macrovascular disease the picture is less clear. In type 1 dia-
betes, long-lasting effects of optimized metabolic control on
the risk of developing CVD have been demonstrated, but this
could be an effectmediated through the effect onmicrovascu-
lar complications. In type 2 diabetes, the combined evidence
from epidemiological studies and intervention trials strongly
indicates an effect of glucose control on risk of CVD. Conse-
quently, there is reason to aim for good glucose control in
both types of diabetes. In type 1 diabetes, glucose control
requires appropriate insulin therapy and concomitant pro-
fessional dietary therapy. In type 2 diabetes, professional
dietary advice, reduction of overweight, and increased phys-
ical activity should be the ﬁrst treatment, followed bypharma-
cological treatment (oral hypoglycaemic treatment and insulin
when needed) aiming at good glucose control. Recommended
treatment targets for type 2 diabetes are given in Table 8. As
to HbA1c and glucose targets, in patients who receive treat-
mentwith insulin or drugs stimulating insulin secretion (sulpho-
nylureas, nateglinide, and repaglinide), special attention
should be paid to avoidance of hypoglycaemic episodes, with
guidance obtained from glucose self-monitoring. Targets for
Table 8 Treatment targets in patients with type 2 diabetes
ESC Guidelines 2399
 at K
atholieke U
niversiteit on D
ecem
ber 3, 2012
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
blood pressure and lipids are generally more ambitious in
patients with diabetes than in non-diabetic subjects.
The metabolic syndrome
Scientiﬁc background
The metabolic syndrome describes the clustering of cardio-
vascular risk factors in individuals with obesity or insulin
resistance. It identiﬁes individuals with increased risk of
developing CVD in accordance with the clustering of risk
factors, but does not indicate risk of CVD over and above
the effect of the risk factors involved.
Practical aspects: management
The diagnosis of the metabolic syndrome is of greatest
importance in non-diabetic subjects as an indicator of an
increased risk of developing type 2 diabetes and CVD. The
interest in the metabolic syndrome should, however, not dis-
place the use of other similar risk scoring tools from their
primary place in the identiﬁcation of individuals at high
risk of CVD. Among different deﬁnitions for the metabolic
syndrome formulated by international and national expert
groups, the original NCEP-ATP III deﬁnition and its revision
recommended by the American Heart Association (AHA)
and NHLBI156,157 (see Table 9) and the deﬁnition created
by the Consensus Panel of the International Diabetes Federa-
tion (IDF)158 (see Table 10) have been developed for clinical
use, but it is important to realize that the prevalence
obtained with these deﬁnitions is far from similar, and indi-
viduals labelled as having the metabolic syndrome will to a
substantial extent be different. The prevalence of the meta-
bolic syndrome is clearly higher with the AHA/NHLBI revision
of the NCEP-ATP III deﬁnition than with the original
NCEP-ATP III deﬁnition and the IDF deﬁnition. This is
mainly caused by the lowered cut-off for impaired fasting
glycaemia in the two new deﬁnitions, but with the IDF deﬁ-
nition the emphasis on central obesity deﬁned by strict
cut-offs also contributes. The original NCEP-ATP III deﬁnition
is more robust in the prediction of CVD risk, with a higher
positive predictive value than the revised NCEP-ATP III deﬁ-
nition and the IDF deﬁnition.
Lifestyle has a strong inﬂuence on all the components of
the metabolic syndrome and, therefore, the main emphasis
in the management of the metabolic syndrome should be in
professionally supervised lifestyle changes, particularly
efforts to reduce body weight and increase physical activity.
Elevated BP, dyslipidaemia, and hyperglycaemia (in the dia-
betic range) may, however, need additional drug treatment
as recommended in the present guidelines.
Psychosocial factors
Scientiﬁc background
There is increasing scientiﬁc evidence that psychosocial
factors contribute independently to the risk of CHD even
after statistical control for the effects of standard risk
factors.159 In addition to increasing the risk of a ﬁrst event
and worsening the prognosis in CHD, these factors may act
as barriers to treatment adherence and efforts to improve
lifestyle, as well as to promote health and well-being in
patients and populations.
The following psychosocial risk factors have been shown
to inﬂuence both the risk of contracting CHD and the wor-
sening of clinical course and prognosis in patients with CHD:
† Low socio-economic status
† Social isolation and lack of social support
† Stress at work and in family life
† Negative emotions including depression and hostility.
Table 10 The IDF deﬁnition of the metabolic syndrome
Central obesity deﬁned by ethnic-speciﬁc waist circumference
criteria 94 cm in Europid men, 80 cm for Europid women
and any two of the following four components:
Elevated triglycerides: 1.7 mmol/L (150 mg/dL) or speciﬁc
treatment for this lipid abnormality
Low HDL cholesterol: ,1.03 mmol/L (,40 mg/dL) in men,
,1.29 mmol/L (,50 mg/dL) in women or speciﬁc treatment
for this lipid abnormality
Raised blood pressure: systolic BP .130 mmHg and/or diastolic
BP .85 mmHg, or treatment of previously diagnosed
hypertension
Impaired fasting glycaemia: fasting plasma glucose 5.6 mmol/L
(100 mg/dL) or previously diagnosed type 2 diabetes
Table 9 Original and revised NCEP-ATP III deﬁnitions of the
metabolic syndrome
At least three of the following ﬁve components
Central obesity: waist circumference .102 cm in men, .88 cm
in women
Elevated triglycerides: 1.7 mmol/L (150 mg/dL)
Low HDL cholesterol: ,1.03 mmol/L (,40 mg/dL) in men,
,1.29 mmol/L (,50 mg/dL) in women
Raised blood pressure: systolic BP 130 mmHg and/or diastolic
BP 85 mmHg, or treatment of previously diagnosed
hypertension
Impaired fasting glycaemia: fasting plasma glucose 6.1 mmol/L
(110 mg/dL) [5.6 mmol/L (100 mg/dL)]a or previously
diagnosed type 2 diabetes
aThe revised version recommended by the AHA/NHLBI uses the lower
cut-off for impaired fasting glycaemia.
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It is now evident that psychosocial risk factors do not occur
in isolation from one another, but tend to cluster in the same
individuals and groups, for example, those with low SES. In
addition to risky health behaviours such as smoking and
unhealthy nutrition, persons with psychosocial risk factors
such as depression are also more likely to express physiologi-
cal characteristics such as autonomic, endocrine, and inﬂam-
matory changes that are involved in promoting CVD.
Evidence is also accumulating of therapeutic and preven-
tive intervention methods that counteract psychosocial risk
factors and promote healthy behaviours and life-
style.44,45,160 Several psychosocial interventions have been
shown to have beneﬁcial effects on distress and physiologi-
cal risk factors,44,46 and some studies also showed improved
CVD outcomes, especially in white men and in patients who
achieved the proximal goals of the intervention. Speciﬁc
behavioural group treatments for women with CHD may be
useful for reducing distress and exhaustion. In patients
with CHD and severe co-morbid depression, selective seroto-
nin re-uptake inhibitors can be given to treat depression and
improve quality of life. Results from non-randomized trials
indicate that these substances may also improve prognosis
in depressed patients.
Practical aspects: management of psychosocial risk
factors in clinical practice
† Assess all patients for psychosocial risk factors, e.g.
depression and hostility, low SES, social isolation, and
chronic life stress by clinical interview or standardized
questionnaires. A selection of screening instruments is
given in Albus et al.161
† Core questions for the assessment of psychosocial risk
factors include the following. It should be noted that
these rather blunt questions will need to be phrased
with sensitivity if a constructive rapport with the
patient is to be established:
† Low SES. Do you have no more than mandatory edu-
cation? Are you a manual worker?
† Social isolation. Are you living alone? Do you lack a
close conﬁdant? Do you lack any person to help you in
case of illness?
† Work and family stress. Do you have enough control
over how to meet the demands at work? Is your
reward appropriate for your effort? Do you have
serious problems with your spouse?
† Depression. Do you feel down, depressed, and hope-
less? Have you lost interest and pleasure in life?
† Hostility. Do you frequently feel angry over little
things? If someone annoys you, do you regularly let
your partner know? Do you often feel annoyed about
habits other people have?
† Discuss relevance with patient in respect to quality of life
and medical outcome.
† Use principles of enhanced communication and beha-
vioural counselling as described above.
† Patients with low SES need special preventive effort.
† In patients at high risk or those with established CVD and
psychosocial risk factors, prescribe multimodal, behavioural
intervention, integrating individual or group counselling for
psychosocial risk factors and coping with stress and illness.
† Refer to a specialist in the case of clinically signiﬁcant
emotional distress. Patients with clinical depression
should receive treatment with psychotherapy or anti-
depressant medication, preferably selective serotonin
re-uptake inhibitors, according to established guidelines.
Those not accepting treatment should be closely followed
and treatment offered again if depression persists for
more than 4–6 weeks.
Inﬂammation markers and haemostatic factors
Scientiﬁc background
Risk factors may be classed into several hierarchical cat-
egories as follows: classical, established, emerging, and
putative, and also as risk markers. The highest level of
classiﬁcation achieved thus far by the heterogeneous
group of factors discussed in these guidelines is ‘emerging’,
but many are under active investigation in clinical and epi-
demiological studies. These factors are associated with
many different biological systems such as those regulating
platelets, coagulation, ﬁbrinolysis, endothelial function,
and the inﬂammatory response. These interact in ways
which remain incompletely understood, but in which scien-
tiﬁc interest and achievement is considerable. In addition
to their potential utility in long-term risk prediction of
CVDs, close associations between inﬂammatory markers
and obesity and diabetes have been demonstrated, which
strengthens the case for their scientiﬁc investigation.
There is strong evidence from pathological162,163 and epi-
demiological studies164–167 that the circulating markers of
activated inﬂammation and haemostasis are closely associ-
ated with the development of fatal and non-fatal MI. A
large case series, based in a national primary care database,
showed that ﬁrst MI and stroke were each more common fol-
lowing recent respiratory or urinary tract infections, the risk
being greatest within the ﬁrst 3 days after diagnosis (rela-
tive risks 5.0 and 3.2, respectively), and falling during the
following weeks.168 A recent report from Europe, as part
of the WHO’s MONICA study, showed that population levels
of certain haemostatic factors differed between participat-
ing centres and countries, and showed signiﬁcant associ-
ations with the incidence of CHD in the centres.
Prospective epidemiological studies have also linked
inﬂammatory markers with the development of type 2 dia-
betes mellitus, and interleukin-6 (IL-6), a pro-inﬂammatory
cytokine, with CHF. Some studies have demonstrated that
risk prediction for CHD, and for both CHD and stroke can
be improved by the addition of these newer risk factors to
risk models which include all established risk factors. A
recent report in the USA proposed that CRP should be used
as an ‘option’ in current guidelines,169 but this proposal
has been questioned both in the USA and in Europe.170,171
Incorporation of CRP and other emerging risk factors into
routine practice for prediction of cardiovascular risk may be
premature, therefore, and criteria for the rigorous evalu-
ation of such factors have been proposed. These criteria
include: applicability to all relevant clinical cardiovascular
events; ability to predict in short, intermediate, and long-
term follow-up; standardized measurements; examination
of variability; the degree of correlation with established
risk factors; and improvement in overall prediction, among
other criteria. A number of meta-analyses of observational
epidemiological studies have been conducted, e.g. for
CRP172 and for ﬁbrinogen.173 Such meta-analyses will
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provide evidence of the possible utility of emerging risk
factors in future clinical practice; but current investigations
of determinants of inﬂammatory markers, which include
physical activity, dietary factors, alcohol, and weight loss
as protective factors, and infections such as periodontitis
as a potentially treatable risk factor, encourage the detailed
examination of this group of markers in future research.
Another important point regarding these meta-analyses is
that CRP (as well as ﬁbrinogen and possibly other bio-
markers) is often seriously confounded by other unmeasured
variables and subject to reverse causality (i.e. pre-clinical
disease causes rises in CRP). Consequently, large-scale
meta-analyses, like those cited above, fall into the trap of
promoting the idea that the evidence of a causal link is
strong. An alternative approach, examining genotypes
directly, has been carried out by several groups, demon-
strating that predicted associations between CRP genotypes
that code for higher levels of circulating CRP are not
associated with CVD or risk factors. However, a large
meta-analysis of seven haemostatic genes showed that var-
iants of factor V gene and of the prothrombin gene may be
moderately associated with risk of coronary disease.174
Genetic factors
Genetic information is divided into three categories: family
history, phenotypes, and genotypes.
Family history: scientiﬁc background
Some studies have established the importance of family
history as a coronary risk factor for CHD, and have shown
that the risk associated with family history of early CHD
(in ﬁrst-degree relatives, male ,55 years and female ,65
years) ranges between 1.5 and 1.7 and is independent of
classical CHD risk factors.175,176
The risk of CHD increases with a positive history
† in a ﬁrst degree relative (parents, son, daughter, brother
or sister), in a second degree relative (grandparents, aunt
or uncle), or in a third degree relative (cousin);
† as the number of family members with CHD increases; and
† the younger the age at which family members develop
CHD.
Family history: practical aspects
Risk factor assessment, and a family history of premature
CHD, including a detailed history and a drawing of a pedi-
gree, should therefore be carried out in the ﬁrst degree
relatives of any patient developing coronary disease
before 55 years in men and 65 years in women. Lifestyle
advice and, where appropriate, therapeutic management
of risk factors should be offered to members of families
where coronary disease is highly prevalent.
Phenotypes: scientiﬁc background
The study of the genetic determinants of ‘phenotypes’
which are involved in the pathophysiology of CHD (dyslipi-
daemia, hypertension, endothelial dysfunction, diabetes,
cardiac and vascular hypertrophy, and atherosclerosis) is
likely to be clinically relevant, and each has its own
genetic and environmental determinants.
For many of these phenotypes (measurable traits) there
is a good evidence for a relatively strong genetic determi-
nation, which is usually estimated by ‘heritability’. For
example, for apoproteins and lipid traits, heritability varies
between 40 and 60%;177 for plasma Lp(a), heritability is
.90%.178 Since meta-analyses show that levels of Lp(a) are
associated with a 1.6-fold greater risk of CHD,179 an effect
which is of similar magnitude to smoking, the Lp(a) gene
would appear to be a major genetic factor for CHD.
The data suggest a moderate to high heritability for emer-
ging risk factors such as intercellular adhesion molecule
(ICAM), IL-6, phospholipase A2 (PLA2), etc.180,181
Genotypes: scientiﬁc background
The levels of CHD risk traits are inﬂuenced by both environ-
mental and genetic factors. The concept of gene–
environment interaction is necessary to understand how
genetic information can be used for accurate risk assess-
ment,182 and this is likely to be of major research import-
ance in the future. Genetic polymorphisms are deﬁned as
sequence variants that occur at a frequency .1%. These
include single nucleotide polymorphisms (SNPs) as well as
insertion/deletion and copy number variants which have
recently been reported to be very common.183
A large number of ‘candidate’ genes have already been
investigated in relation to CHD traits and to risk of CHD
itself.
Several variants in genes involved in lipid metabolism [e.g.
apolipoprotein E (APOE), apolipoprotein B (APOB), lipoprotein
lipase (LPL), cholesterol ester transfer protein (CETP)], coagu-
lation [plasminogen activator inhibitor 1 (PAI1), glycoprotein
IIb/IIIa (GIIb/IIIa), factorV (FV)], anddifferent aspects of endo-
thelial function [endothelial nitric oxide synthase (eNOS),
methylenetetrahydrofolate reductase (MTHFR) and ACE]184
appear to be associated with statistically signiﬁcant, although
rather modest effects on risk.
DNA-based tests for risk prediction
Currently available CHD risk prediction algorithms based on
classical risk factors185,186 have a very low prediction rate,
for example 11% in a 10-year follow-up of UK healthy men,
and adding risk genotypes may improve this.187
Modelling has suggested188 that only around 20 genes are
needed to explain 50% of the burden of a disease in the
population if the predisposing genotypes are common
(.25%), even if the individual risk ratios are relatively
small (i.e. increasing risk by only 20–50%).
Practical aspects
DNA-based tests for risk prediction
At the moment, DNA-based tests do not add signiﬁcantly to
diagnostic utility or patient management. In the long term,
understanding disease aetiology in terms of genetic determi-
nants may be useful in identifying high risk individuals and
adapting therapeutic management to the individual’s
genetic make-up.
Pharmacogenetics
Currently, there are few data either for the most effective
choice of available drugs based on an individual’s genetic
make-up, or for the avoidance of dangerous side effects in
the ﬁeld of CVD.
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The full potential of this ﬁeld will only be realized with
much further work.
Severe familial dyslipidaemias and coronary
heart disease
There are many extremely rare inherited conditions where
plasma lipids are abnormal and CHD risk is altered. Here
we focus on only the three most common of these.
Familial hypercholesterolaemia (FH)
Scientiﬁc background: FH has an estimated prevalence of
1/500.189 It is characterized by hypercholesterolaemia due
to increased LDL levels, xanthomas, premature CHD, and a
family history of one or more of these. Angina, heart
attacks, or death typically occur in men between 30 and
50 years, and in women between 50 and 70 years,190 and
those who smoke, are hypertensive, or have other risk
factors are at particularly high risk. Several methods with
different sensitivity and speciﬁcity have been developed
for the clinical diagnosis of FH,191–193 but the ‘gold standard’
is a combination of clinical and biochemical factors and the
presence of a detectable disease-causing DNA change, which
gives the highest clinical utility.
FH is anautosomal dominant inheriteddisorderand is usually
caused by a mutation in the LDL receptor gene (LDLR). To
date,. 700 different mutations have been identiﬁed world-
wide (see http://www.ucl.ac.uk/fh), although the spectrum
within a single country ismuch smaller.194,195 Screening for del-
etions and rearrangements of the LDLR gene using a technique
called multiplex ligation-dependent probe ampliﬁcation
(MLPA)196 has become available, and it is known that up to 5%
of FH patients may have such a deletion.197
A speciﬁc mutation occurs in the apolipoprotein B 100
gene (APOB), the ligand for the LDL receptor, in approxi-
mately 3% of FH patients in the UK, North Europe, and the
USA. The disorder has been designated familial defective
apolipoprotein B 100 (FDB).198 FDB is milder than LDLR-FH
but hypercholesterolaemia occurs in childhood and early
CHD occurs in some subjects.
Recently, defects in a third gene called protein convertase
subtilisin/kexin type 9 (PCSK9), causing monogenic hyperch-
olesterolaemia, have been identiﬁed.199 These mutations
could cause increased degradation of LDL receptors,
reduced numbers of receptors on the surface of the cell,
and monogenic hypercholesterolaemia.
Using currently available routine clinical genetic diagnos-
tic techniques,192–194 it is possible to demonstrate a
mutation in the LDLR, PCSK9, or APOB gene in up to 80–
90% of clinically diagnosed patients, but this is usually only
available in a research setting. Such specialist services are
available in several European countries,194,195,200–202 but
each country should have its own programme for genetic
testing for FH because the spectrum of mutations varies
between countries.
Current data strongly suggest that DNA testing for FH
complements cholesterol measurement in cascade screening
to identify affected subjects unambiguously.203,204
Practical aspects: Because of their high CHD risk, patients
with FH should be aggressively treated with statins at a
young age. Lifestyle advice should be offered and sup-
ported. Cascade testing to identify affected relatives
should be undertaken. It is likely that, for optimal diagnostic
and management results, both phenotypic and genotypic
diagnosis should be used.
Familial combined hyperlipidaemia (FCH)
Scientiﬁc background: This is the most common of the
severe hyperlipidaemias, with a prevalence of perhaps 1/
100.205 FCH is likely to be more polygenic/multifactorial
than FH. A major gene determining the FCH phenotype has
been found in Finnish families, identiﬁed as the gene for
upstream regulatory factor 1 (USF1)—a major controller of
lipid and glucose homeostasis.206
Despite no speciﬁc mutation within the USF1 gene being
identiﬁed in FCH patients, a common haplotype composed
of several SNPs is associated with risk of developing FCH.207
Practical aspects: Because of their high CHD risk, patients
with FCH should be treated with lipid-lowering therapy and
lifestyle advice. There is currently little experience to
support the clinical utility of cascade testing to identify
affected relatives, but this is likely to be beneﬁcial.
Familial high-density lipoprotein deﬁciency syndromes
Scientiﬁc background: The inverse and independent associ-
ation between HDL cholesterol and the risk of fatal and
non-fatal CHD events has been established by clinical and
epidemiological studies. A low HDL cholesterol level
,35 mg/dL (0.9 mmol/L) has become part of the multipara-
metric algorithms used for CVD risk estimation.185,186
Patients with HDL cholesterol levels below the 5th percen-
tile within a given population can be assumed to have mono-
genic HDL deﬁciency.208
Practical aspects: Rule out secondary causes and perform
a careful physical examination in patients with the virtual
absence of HDL. Family studies should be initiated, to
demonstrate the vertical transmission of the low HDL
cholesterol phenotype. Since currently there is no routinely
used drug available to increase HDL cholesterol levels in
patients with familial low HDL cholesterol, these patients
should be treated for additional risk factors.
New imaging methods to detect
asymptomatic individuals at high risk
for cardiovascular events
Scientiﬁc background
One of the major objectives of a CVD detection programme
should be to identify those apparently healthy individuals
who have asymptomatic arterial disease in order to slow
the progression of atherosclerotic disease, to induce
regression, and in particular to reduce the risk of clinical
manifestations. The revolution in technology has clearly
inﬂuenced the decision making of cardiovascular patients,
and this can be clearly applied to the early detection of
the disease even in asymptomatic patients.
For coronary artery disease, the consequences of coronary
atherosclerosis can be objectively assessed non-invasively,
using a variety of techniques such as bicycle or treadmill
exercise ECG testing, stress echocardiography, or radio-
nuclide scintigraphy. These techniques are routinely used
in diagnostic work-up programmes in the clinic; they have
rarely been used in the population as screening tools. More
recently, new techniques have become available to detect
coronary lesions.
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MRI has been evaluated as a means of assessing the pre-
sence or absence of coronary artery stenosis. The value of
this technique in detecting coronary artery stenosis is still
in question. Sensitivity, speciﬁcity, and robustness of this
technique are not high enough to perform screening for cor-
onary stenoses in asymptomatic people.
A potentially more useful approach for risk stratiﬁcation
is to perform in vivo imaging of the arterial wall using MRI.
In vitro, MRI is able to differentiate between the plaque
components of carotid, aortic, and coronary artery speci-
mens obtained at autopsy. For the present moment, MRI is
a promising research tool, but its use is limited to only a
small number of research laboratories at this time. Thus,
MRI is not yet appropriate for use in identifying patients at
high risk for coronary artery disease.
Coronary calciﬁcations represent atherosclerosis of coron-
ary arteries. Normally, they occur exclusively as athero-
sclerotic lesions within the intima layer and are not found
in healthy coronary vessel walls. On the other hand, athero-
sclerotic diseased coronary arteries do not necessarily
always show calciﬁcations. The extent of coronary calciﬁca-
tions correlates with the extent of the total coronary plaque
burden. It should be noted that coronary calciﬁcation is an
indicator neither for stability nor instability of an athero-
sclerotic plaque.
Recent developments in technology of the classic CT
resulted in multislice CT devices.215 With the use of MS-CT
it is possible to obtain a clear deﬁnition of the coronary
vessels in most patients. However, the highest value of this
technique seems to be its negative predictive value, reach-
ing close to 98% in some studies. This very high negative pre-
dictive value of the technique leads to the consideration of
using MS-CT for screening in certain subsets of the high risk
population. Still, we need prospective studies to determine
clearly which population may beneﬁt most from this
technology.
Although calcium scanning is widely applied today, it
should not be uncritically used as a screening method.
There is a need for prospective studies that will show the
clear beneﬁt on each individual subgroups in which an
MS-CT scan is useful.
Population-based studies have shown a correlation
between the severity of atherosclerosis in one arterial terri-
tory and involvement of other arteries. Atherosclerotic
lesions of carotid arteries in the legs are more accessible
for non-invasive examinations than those in coronary or
intra-cerebral arteries. Therefore, early detection of arter-
ial disease in apparently healthy individuals has also focused
on the peripheral arterial territory and on the carotid
arteries. Recently, plaque characteristics as assessed by
carotid ultrasound were found to be predictive of sub-
sequent cerebral ischaemic events. Patients with echo-
lucent stenotic plaques had a much higher risk of stroke
and cerebrovascular events than subjects with other
plaque types.
An ankle–brachial index (ABI) ,0.9 reﬂects 50% stenosis
between the aorta and the distal leg arteries. Because of its
high sensitivity and speciﬁcity (both .90%), an ABI .0.90 is
considered a reliable sign of peripheral vascular disease. In
asymptomatic individuals over 55 years of age, an ABI
,0.9 may be found in 12–27%. Even in an elderly population
(71–93 years), a low ABI further identiﬁes a higher risk CHD
subgroup.
Recently it has been shown that the extent of athero-
sclerosis of retinal arteries correlates with the extent of
the total coronary plaque burden. Atherosclerosis of
retinal arteries also strongly correlates with plasma total
cholesterol, LDL cholesterol, triglycerides, and apoprotein
B levels. Since ophthalmoscopy is a non-invasive technique,
is easy to perform, and has no adverse effects, it might be
used to detect asymptomatic individuals at high risk for car-
diovascular events.216,217
Gender issues: cardiovascular disease
prevention in women
Scientiﬁc background
More women than men die from CVD, although they do so at
an older age. CHD is slightly more common as a cause of
death in women, and stroke markedly more common. In con-
trast, breast cancer accounts for only 3% of all deaths in
women. CVD risk in women is deferred by 10 years compared
with that of men. A 55-year-old woman is identical in terms
of risk to a 45-year-old man. The decline in CVD mortality in
recent years has been greater in men than in women, and
CVD incidence has actually increased in women, especially
in the oldest groups.209,210
† Systolic hypertension becomes more frequent in older
women.
† The use of oral contraceptives increases the CVD risk
associated with smoking.
† Total cholesterol levels peak at around 60 years of age in
women, about 10 years later than in men.211
† Diabetes carries a considerably greater risk of fatal CVD in
women.
† Obesity is more prevalent in middle-aged and elderly
women.
In general, women are disadvantaged at all stages of the
clinical evolution of CVD.212 Risk management advice, par-
ticularly with regard to drug therapy, is hampered by defec-
tive evidence, as women are frequently under-represented
in therapeutic trials, and there may be gender differences
in therapeutic response.213 Aspirin reduces the risk of
stroke in women but not the risk of an AMI.214 For women
without CVD, lipid lowering may not affect total or CHD mor-
tality. For women with known CVD, treatment of hyperlipi-
demia is effective in reducing CHD events, CHD mortality,
non-fatal MI, and revascularization, but does not affect
total mortality.
Practical aspects
(1) European and national public health policy needs to
address the problem of inadequate recognition of the
size of the problem of CVD in women and to reﬂect
this through publicity and education of both the public
and the medical profession.
(2) Clinicians should make a speciﬁc point of assessing risk
in female patients.
(3) The principles of total risk estimation and management
are the same for both sexes, with particular emphasis on
the evaluation of smoking, overweight, the use of oral
contraceptives, and glucose tolerance in women.
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(4) A low absolute risk in a young woman may conceal a
large relative risk that will result in high absolute risk
as she ages. Therefore, effective management of
lifestyle change is in general more important than drug
treatment in order to avoid a high absolute risk in
older life.
(5) Extrapolating the results of lipid-lowering trials to young
or middle-aged women without other risk factors may
lead to substantial overuse of cholesterol-lowering
drugs.
(6) Hormone replacement therapy has not been associated
with a reduction in cardiovascular risk, although it
might be indicated for menopausal symptomatic relief.
Renal impairment as a risk factor in
cardiovascular disease prevention
Scientiﬁc background
Renal impairment is associated with the development of CVD
and death. The increased risk is already present by the time
microalbuminuria develops. The risk progressively increases
as renal function deteriorates, and end-stage renal disease
(ESRD) is associated with a CVD risk up to 20–30 times that
of the general population.218 The association between
impaired renal function and increased CVD risk is seen in
the general population, hypertensives, and patients with
pre-existing CVD. The development of renal impairment is
associated with risk factors including age, hypertension,
dyslipidaemia, and the metabolic syndrome, which are
also CVD risk factors.219,220 Therefore, the two diseases
can develop in parallel. Once ESRD has developed, other
factors such as alterations in calcium phosphate homeostasis
and anaemia also contribute to CVD risk.221,222 In heart
failure patients, renal function is independently associated
with risk of death, CVD death, and hospitalization.
Practical aspects: management
The estimated glomerular ﬁltration rate (eGFR) and
presence of either microalbuminuria (30–300 mg/24 h) or
macroalbuminuria (.300 mg/24 h) are used to assess
the stage of renal impairment. An eGFR ,60 mL/min is
associated with signiﬁcant CVD risk. Microalbuminuria
often accompanies reduced eGFR, and the combination of
the two is associated with an additive effect on CVD risk.
An early attempt to control CVD risk factors in patients
with renal impairment is needed. Patients with renal impair-
ment and CHD or heart failure may not be treated with all
appropriate medications.223 Particular attention to ensuring
these patients are prescribed all necessary therapeutic
interventions will improve survival.224
Cardioprotective drug therapy
Scientiﬁc background
The use of prophylactic drugs which have been shown to
reduce morbidity and mortality in clinical trials should be
considered, in addition to drugs used for treatment of elev-
ated blood pressure, lipids, and glucose.
Antiplatelet therapies
In patients with atherosclerotic disease, platelet-modifying
drugs result in a signiﬁcant reduction in all causes of mor-
tality, vascular mortality, and non-fatal MI and stroke.225
Addition of clopidogrel has been proven to be beneﬁcial in
acute coronary syndromes.226 In chronic stable atherosclero-
tic disease, combination of aspirin and clopidgrel is not
associated with a signiﬁcant beneﬁt in terms of MI, stroke,
or CVD death, but is associated with an increased bleeding
risk. In asymptomatic individuals, aspirin reduced MI and
death from CHD, but increased haemorrhagic strokes and
gastrointestinal (GI) bleeding.
b-Blockers
Meta-analyses have demonstrated the beneﬁt of b-blockers
in those post-MI, in terms of all-cause mortality, reinfarc-
tion, and CHD death.87 (DAVIT trials show that verapamil
can be considered as an alternative in those post-MI with
contraindications to b-blockers.) In CHF patients,
b-blocker therapy has been shown to reduce all-cause
mortality.
ACE inhibitors
In heart failure patients or those with left ventricular dys-
function, ACE inhibitors have been shown to reduce risk of
death, recurrent MI, and progression to persistent heart
failure.227 ACE inhibitor treatment also reduced risk of
death after AMI. Studies assessing the beneﬁt of ACE inhibi-
tors in those with stable coronary disease without left ven-
tricular dysfunction have yielded varying results. In
PROGRESS, patients with previous CVD, BP lowering using
ACE inhibitor/diuretic combination showed signiﬁcant
reductions in stroke and coronary disease events. In HOPE,
in diabetics aged over 55 with one additional risk factor
and without left ventricular dysfunction or uncontrolled
hypertension, ACE inhibitors reduced risk of death and MI.106
Anticoagulation
Systemic anticoagulation is indicated, particularly in
combination with aspirin, in patients post-MI whose risk of
thromboembolism is increased.228
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Practical aspects: management
Antiplatelet therapy: aspirin
Indicated in:
(1) All with established CVD (including diabetics) unless
contra-indicated; lifelong treatment with low dose
(75–150 mg daily) is recommended.
(2) Asymptomatic individuals, aspirin should only be con-
sidered when the 10-year risk of CVD mortality is mark-
edly increased and the BP is controlled.
Antiplatelet therapy: clopidogrel
Indicated in:
(1) Cases of aspirin allergy.
(2) In addition to aspirin, in acute coronary syndromes for
9–12 months.
(3) Combination of aspirin and clopidogrel is not routinely
recommended in chronic stable atherosclerotic disease.
b-Blockers
Indicated in:
(1) Patients post-MI (including diabetics).
(2) CHF patients.
(3) Angina to relieve the symptoms of myocardial
ischaemia.
(4) As an antihypertensive (other antihypertensives pre-
ferred in diabetics).
ACE inhibitors
Indicated in:
(1) Treatment of heart failure or left ventricular
dysfunction.
(2) Diabetics to reduce BP to target or if type 1 (and possibly
type 2) nephropathy.
(3) To reduce BP to target. Angiotensin receptor blockers
can be used in patients with an indication for ACE inhibi-
tors but who cannot tolerate ACE inhibitors.
Calcium channel blockers
Indicated for:
(1) Reducing BP to target.
(2) Post-MI if b-blockers are contra-indicated.
Diuretics
Indicated for:
(1) Reducing BP to target. (Alternative antihypertensives
are preferred in type 2 diabetes or those at high risk
of developing type 2 diabetes.)
Anticoagulation
Indicated in:
(1) History of thromboembolic events
(2) Left ventricular thrombus
(3) Persistent or paroxsymal atrial ﬁbrillation – see ESC
guidelines on atrial ﬁbrillation229 (Table 11)
(4) Consider in:
(i) large anterior MI
(ii) left ventricular aneurysm
(iii) paroxysmal tachyarrythmias
(iv) post-MI CHF
Implementation strategies
Scientiﬁc background
Several studies have been carried out to evaluate the effect
of different implementation strategies of guidelines on clini-
cal practice.
EUROASPIRE I (1995/96)39 and II (2000/01)38 surveys both
showed a high prevalence of unhealthy lifestyles, modiﬁable
risk factors, and inadequate use of drug therapies to achieve
Table 11 Indications for antithrombotic therapy in patients with
atrial ﬁbrillation
Risk category Recommended therapy
No risk factors Aspirin, 81 to 325 mg
daily
One moderate risk
factor
Aspirin, 81 to 325 mg
daily, or warfarin (INR
2.0 to 3.0, target 2.5)
Any high risk factor
or more than 1
moderate risk
factor
Warfarin (INR 2.0 to 3.0,
target 2.5)a
Less validated
or weaker risk factors
Moderate risk
factors
High risk
factors
Female gender Age  75 years Previous
stroke, TIA
or embolism
Age 65 to 74 y Hypertension Mitral stenosis
Coronary artery
disease
Heart failure Prosthetic
heart valvea
Thyrotoxicosis LV ejection fraction 35%
or less
Diabetes mellitus
aIf mechanical valve, target international normalized ratio (INR) greater
than 2.5.
bLV ¼ left ventricular; TIA ¼ transient ischaemic attack.
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BP and lipid goals in patients with established CHD, with
wide variations in medical practice between countries.
Many surveys have shown similar results, some also
showing great variance between countries.
There is considerable potential throughout Europe in cor-
onary patients and their families to raise the standard of
preventive cardiology through more lifestyle intervention,
control of other risk factors and optimal use of prophylactic
drug therapies in order to reduce the risk of recurrent
disease and death. Similar results have been shown for
stroke.
Although the availability of systematic reviews and guide-
lines reduces the need for doctors to read original studies,
they still ﬁnd it difﬁcult to keep up with such syntheses.
Even if doctors are aware of the evidence and are willing
to change, to alter well established patterns of care is difﬁ-
cult, especially if the clinical environment is not conducive
to change.
Barriers to the implementation of guidelines
It is essential that clinical guidelines are in concordance
with priorities in the health system and with ethical values
most clinicians can agree upon. If not, this may be an
important reason why many clinicians do not follow
guidelines.230
The implementation of these guidelines should be based
on national surveys to adjust them to the stratiﬁcation of
risk factors and premature CVD death in the individual
country and bring them in accordance with priorities set
by the health authorities and the professional bodies. The
workload put on the health system should be affordable
and should not imply that resources should be allocated to
prevention strategies when the outcome for the population
is better by alternative use.
Analyses of the barriers to changing practice, have shown
that obstacles to change in practice can arise at different
stages in the health care organization, or the wider environ-
ment. Most theories on implementation of evidence in
health care emphasize the importance of developing a
good understanding of such obstacles to develop an effec-
tive intervention.
Doctor–patient relationship
The preventive interventions must be based on a patient-
centred approach, where the doctor pays full attention to
appraise and meet the patient’s concerns, beliefs, and
values, and respects the patient’s choice even if it is not
in concordance with the doctor’s ﬁrst proposal. The chan-
ging of lifestyle or taking medication often means for the
rest of the patient’s life, so the decision must be owned
by the patient. Therefore, treatment goals should be set
in collaboration with the patient, taking into account the
values and priorities of the patient. If the treatment goals
are unaffordable, it may lead to frustration and clinical
neglect, both by the doctor and by the patient. The
doctor should explore the patient’s important values,
beliefs, and expectations regarding the prevention measures
to be taken.
Practical aspects
Important arenas for training
There is a need for training of doctors in patient-centred
preventive care, with emphasis on
† patient-centred methods in the consultation process
† the motivation to change—how to support and strengthen
the patient’s decision to adopt healthy habits
† how to evaluate multifactorial risk and use risk charts
† how to communicate risk and the effects of interventions
† how to discuss treatment goals and follow-up.
Implementation strategies
(1) On the European (international) level:
(a) Publication of the guidelines in relevant journals.
(b) Presentation at international conferences arranged
by the participating societies.
(c) Involvement in policy at European Union level
through, for example, the Luxembourg Declaration
and the development of the European Heart Health
Charter.
(2) On the national level:
(a) If not already existing, implementation demands a
leading expert group of national organizations
representing similar groups to the European Task
Force. The group should have acceptance and
support from national health authorities.
(b) Adjustment and application of national standards, in
accordance with the European Guidelines.
(c) Further implementation should be organized by the
National Colleges in accordance with the local
needs, see below.
Implementation strategies should consist of a package of
different measures, working in combination:
(1) A public health approach, with emphasis on smoking ces-
sation, healthier food and better access to physical
activity in all ages should be implemented—to support
and complement the individual-oriented high risk strat-
egy of doctor-initiated prevention.
(2) A public information campaign of the Fourth Joint CVD
Prevention Guidelines and the corresponding national
Guidelines with two main topics:
(a) Information on the concept of multiple risk assess-
ment and treatment, and the intervention
thresholds.
(b) What people can do to reduce risk.
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The message should encourage people at high risk to realize
their risk and go to see a doctor, but should reassure people
with low risk that they can stay healthy without the doctor’s
help.
(3) An information and education programme aimed at
practising doctors (GPs, internists, and others). It
should consist of a selection of the effective strategies
mentioned above:
(a) Lectures and CME activities with interactive
participation.
(b) Audit and feedback, preferably combined with out-
reach visits by trained colleagues.
(c) Dissemination of electronic versions, applicable to
hand-held equipment.
(d) Dissemination of simple, one-sheet versions of risk
algorithms and treatment recommendations.
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